Cancer Incidence and Mortality in New Jersey, 2008-2012

Cancer Epidemiology Services
Public Health Services Branch
New Jersey Department of Health





Cancer Incidence in New Jersey 2008 - 2012

Prepared by:
Karen Pawlish, ScD, MPH
Xiaoling Niu, MS
Jie Li, MPH
Sumathy Vasanthan, MS
Stasia S. Burger, MS, CTR
Lisa Paddock, PhD, MPH
Pamela K. Agovino, MPH
Stephanie Hill, MPH, CTR
Antoinette Stroup, PhD

Cancer Epidemiology Services Public Health Services Branch New Jersey Department of Health

Christina G. Tan, MD, MPH State Epidemiologist/Assistant Commissioner

> Mary O'Dowd Commissioner

Chris Christie, Governor Kim Guadagno, Lt. Governor

Cancer Epidemiology Services New Jersey Department of Health PO Box 369 Trenton, NJ 08625-0369 (609) 633-0500 http://nj.gov/health/ces/index.shtml

August 2015

ACKNOWLEDGMENTS

The following staff of the New Jersey State Cancer Registry and the Cancer Research Program of the Cancer Epidemiology Services, the Cancer Surveillance Unit of the Consumer, Environmental and Occupational Health Services and the Rutgers Cancer Institute of New Jersey were involved in the collection, quality assurance and preparation of the data on incident cases of cancer in New Jersey:

Nahrin Ahmed, MA Ilsia Martin, MS

Adrian Botchway Kevin Masterson, CTR
Nicole Chiavarone Nicole McAnaney
Rudmila Chowdhury, CTR John Murphy, CTR

Patricia Davis

John Murphy, CTR

Manisha Narang, MPH

Thomas English, CTR

Raj Gona, MPH, MA

Cynthia Nunez

Maithili Patnaik, CTR

Raj Gona, MPH, MA

Maithili Patnaik, CTR

Essam Hanani, MD, CTR

Rhena Powell

Denise Hansen, CTR Gladys Pyatt-Dickson, CTR
Marilyn Hansen, CTR Lisa M. Roche, MPH, PhD

Natalia Herman, MPH

Katie Roman

Donna Horn, CTR

Yvette Humphries

Antonio Savillo, MD, CTR

Suzanne Schwartz, MS, CTR

Nicole Jackson Anasuya Shukla

Jamal Johnson, CTR Heather Stabinsky, MS.Ed, CTR

Linda Johnson, CTR

Catherine Karnicky, CTR

Harrine Katz, CTR

Fran Krol, CTR

Hannah Stanko

Neeru Suri

Gabrielle Taylor

Michael Tumblety

Fran Krol, CTR Michael Tumblety
Mireille Lemieux, CTR Renu Verma
Hanry Lewis MPH

Henry Lewis, MPH

Annette Werts
Helen Martin, CTR

We also acknowledge New Jersey hospitals, laboratories, physicians, dentists, and the states of Connecticut, Delaware, Florida, Maryland, New York, North Carolina, and Pennsylvania who reported cancer cases to the New Jersey State Cancer Registry.

Cancer Epidemiology Services, including the New Jersey State Cancer Registry, receives support from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute under contract HHSN 261201300021I and control No. N01PC-2013-00021, the National Program of Cancer Registries, Centers for Disease Control and Prevention under cooperative agreement 5U58DP003931-02, the State of New Jersey, and the Rutgers Cancer Institute of New Jersey.

TABLE OF CONTENTS

INTRODUCTION	I
SUMMARY	
TECHNICAL NOTES	
New Jersey State Cancer Registry	7
Data Sources and Specifications	9
Data Presentation	
REFERENCES	14

TABLES

Table 1. Age-adjusted Incidence Rates, Males, All Races Combined	18
Table 2. Age-adjusted Incidence Rates, Females, All Races Combined	20
Table 3. Age-adjusted Incidence Rates, White Males	22
Table 4. Age-adjusted Incidence Rates, White Females	24
Table 5. Age-adjusted Incidence Rates, Black Males	26
Table 6. Age-adjusted Incidence Rates, Black Females	28
Table 7. Age-adjusted Incidence Rates, Hispanic Males	30
Table 8. Age-adjusted Incidence Rates, Hispanic Females	32
Table 9. Age-adjusted Incidence Rates, Asian and Pacific Islander Males and Females, 2008-2012 combined	34
Table 10. Benign and Borderline Brain Tumor Incidence Rates, New Jersey, 2008-2012	36
Table 11. Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders Incidence Rates, New Jersey, 2008-2012	37
Table 12. Distribution of Stage at Diagnosis for Selected Cancer Sites in New Jersey, Males, 2008-2012	38
Table 13. Distribution of Stage at Diagnosis for Selected Cancer Sites in New Jersey, Females, 2008-2012	
Table 14. Comparative Incidence Rates, New Jersey and U.S., Males, 2008-2012	40
Table 15. Comparative Incidence Rates, New Jersey and U.S., Females, 2008-2012	40
Table 16. Age-adjusted Mortality Rates, Males, All Races Combined	42
Table 17. Age-adjusted Mortality Rates, Females, All Races Combined	44
Table 18. Age-adjusted Mortality Rates, White Males	46
Table 19. Age-adjusted Mortality Rates, White Females	48
Table 20. Age-adjusted Mortality Rates, Black Males	50
Table 21. Age-adjusted Mortality Rates, Black Females	52
Table 22. Age-adjusted Mortality Rates, Hispanic Males and Females	54
Table 23. Age-adjusted Mortality Rates, Asian and Pacific Islander, Males and Females, 2008-2012 Combined	56
Table 24. Comparative Mortality Rates, New Jersey and U.S., Males, 2008-2012	58
Table 25. Comparative Mortality Rates, New Jersey and U.S., Females, 2008-2012	58
Table 26. Population Denominators by Race, Age Group and Year	59
Table 27. Age Distribution (%) of Incidence Cases in New Jersey, 2008-2012, All Races, Both Sexes	61
Table 28. Median Age of Cancer Patients at Diagnosis, New Jersey 2008-2012, By Primary Cancer Site, Race and Sex	62

INTRODUCTION

This report presents statewide, age-adjusted incidence rates and counts for all cancers diagnosed among New Jersey residents during the period 2008-2012.

The primary goal of this report is to provide 2008-2012 cancer statistics to healthcare planners, researchers and the public. Statistics are presented statewide for eight population subgroups: white men, white women, black men, black women, Hispanic men, Hispanic women, Asian and Pacific Islander men, and Asian and Pacific Islander women. These statistics are also presented by gender for all races combined. Statistics are presented by stage at diagnosis for selected cancer sites by gender and race/ethnicity.

The age-adjusted incidence and mortality rates per 100,000 population are presented by major cancer sites and for all sites combined by year of diagnosis. Asian and Pacific Islander data are presented for the combined five-year period of 2008-2012. For the incidence counts and rates, *in situ* cancers are not included except for bladder cancer *in situ* cases, which are included with invasive urinary bladder, urinary system and all sites. Breast cancer *in situ* cases for women are shown but not included in the totals for all sites combined. Basal and squamous cell skin cancers are not collected and therefore not included in the tables. Benign and borderline brain tumor incidence data for 2008-2012 are presented separately. Myelodysplastic syndromes (MDS) and chronic myeloproliferative disorders (CMD) are defined as malignant starting in 2001 with ICD-O-3 and are included in "All Sites" and in the "Ill Defined" category in the rate tables. MDS and CMD incidence rates are presented separately. These conventions are standard practice for publication of cancer rates in the United States.

Additional New Jersey cancer incidence, mortality, survival, and prevalence data are available from the Cancer Epidemiology Services office or on our website, http://nj.gov/health/ces/index.shtml, including:

- Cancer Survival in New Jersey, 1979-2005;
- Cancer Prevalence in New Jersey, 1/1/2009;
- Cancers with Population-Based Screening Methods Incidence, Stage at Diagnosis, and Screening Prevalence, New Jersey;
- Cancer Among Asians and Pacific Islanders in New Jersey, 1990-2007;
- Adolescent and Young Adult Cancer in New Jersey 1979-2006;
- Childhood Cancer in New Jersey, 1979-2005; and
- Area Socioeconomic Variations in Cancer Incidence and Stage at Diagnosis in New Jersey, 1996-2002.

Our interactive cancer statistics mapping application provides incidence and mortality counts and rates statewide and at the county level by year, age, sex, race, and ethnicity for the years 1990 and later at http://nj.gov/health/ces/cancer-rates.shtml. Other New Jersey and U.S. cancer data can be found on the following websites:

• Cancer Control Planet, http://cancercontrolplanet.cancer.gov/

- North American Association of Central Cancer Registries' *Cancer in North America 2008—2012*,
 - http://www.naaccr.org/DataandPublications/CINAPubs.aspx
- Surveillance, Epidemiology and End Results (SEER) Program's *Cancer Statistics Review*, http://www.seer.cancer.gov/
- Centers for Disease Control and Preventions, *United States Cancer Statistics*, http://apps.nccd.cdc.gov/uscs/index.aspx
- State Cancer Profiles, http://statecancerprofiles.cancer.gov/

SUMMARY

Cancer Incidence, New Jersey 2008-2012

A total of 48,481 cases of invasive cancer diagnosed in 2012 among New Jersey residents were reported to the New Jersey State Cancer Registry (NJSCR), which is slightly lower compared to 49,004 reported cases diagnosed in 2011. During the period 2008-2012, a total of 244,532 cases of invasive cancer were diagnosed among New Jersey residents, 50.2% among men and 49.8% among women, 83.8% among whites, 11.1% among blacks, and 3.5% among Asians and Pacific Islanders (API). Hispanics of any race accounted for 8.3% of the total cancer cases.

Primary cancers with the ten highest age-adjusted incidence rates during 2008-2012 in New Jersey were prostate, lung, colon and rectum, urinary bladder, melanoma of the skin, non-Hodgkin lymphoma, kidney and renal pelvis, leukemia, pancreas and oral cavity and pharynx for men; and breast, lung, colon and rectum, endometrial (corpus and uterus, NOS), thyroid, non-Hodgkin lymphoma, melanoma of the skin, ovary, pancreas, and urinary bladder for women. These accounted for 79% of all incident cancers (Tables 1 and 2).

In New Jersey, the average age-adjusted total cancer incidence rate for men was 564.0 per 100,000 for the years 2008-2012 combined, with decreasing rates since 2008 (Table 1). Lung and colorectal cancer incidence rates among all men continued to decrease during this time period (Table 1). New Jersey prostate cancer incidence rates decreased by approximately 20% from 2011 to 2012. A similar decrease in prostate cancer incidence was observed in other U.S. states in 2012 (Howlader et al., 2015). Thyroid cancer incidence rates continued to increase for all men, especially among white men each year from 2008 to 2012. Thyroid cancer rates for white men were more than double the rates for black men, 10.3 per 100,000 versus 4.1, respectively (Tables 3 and 5). Total cancer incidence rates declined during 2008-2012 for white men and decreased for black men after 2009. Total cancer incidence rates were higher in black men than white men before 2011, while rates were higher in white men during 2011 and 2012. This convergence is fueled by decreasing trends in prostate, lung, colorectal, and laryngeal cancer incidence rates (Tables 3 and 5). Black men still had higher prostate cancer, lung cancer, and multiple myeloma incidence rates and lower bladder cancer, melanoma, and non-Hodgkin lymphoma incidence rates compared to white men (Tables 3 and 5).

The age-adjusted total cancer incidence rates for all New Jersey women remained fairly stable, with a slight decrease after 2009. The average annual incidence rate for New Jersey women was 449.9 per 100,000 women during 2008-2012. Incidence rates for some of the most common cancers, including breast and endometrial, remained stable while decreasing rates were noted for lung, colorectal and cervical cancers among women (Table 2). The total cancer incidence rate, as well as rates of lung, breast, and endometrial cancers and melanoma, for black women continued to be lower compared to white women (Tables 4 and 6). However, black women had higher incidence rates for most digestive system cancers, cervical cancer, and myelomas compared to white women. Thyroid cancer incidence rates increased for all women through 2009. The thyroid cancer rates for white women were more than double the rates for black women, 31.0 per 100,000 versus 12.1, respectively (Tables 4 and 6).

New Jersey Hispanics continued to have lower incidence rates for all cancers combined and for many of the most common types of cancer in the general population, including lung, female

breast, prostate, bladder, and melanoma of the skin (Tables 7 and 8). But Hispanics continued to have higher incidence rates for stomach, liver, and cervical cancers compared with the general population in New Jersey. Among Hispanic men and women, thyroid cancer incidence rates followed an increasing trend similar to New Jersey as a whole (Tables 7 and 8).

New Jersey Asians and Pacific Islanders continue to have much lower cancer incidence rates compared to the general population for all cancers combined and most common types of cancer such as lung, colorectal, female breast and prostate. Stomach, liver and nasopharyngeal cancer incidence rates were higher for Asians and Pacific Islanders than in the general population (Table 9).

A review of the incidence of benign and borderline brain and central nervous system tumors in New Jersey showed that these tumors occurred mostly in intracranial meninges and the sellar region, while invasive brain tumors occurred mostly in the brain proper. This pattern was similar to the results seen in U.S. SEER data (Howlader et al., 2015). New Jersey incidence data for 2008-2012 showed women had higher rates compared to men for these types of tumors and rates were fairly similar among whites and blacks. Women also had higher benign intracranial meningioma incidence rates compared to men during this same time period (Table 10).

A review of myelodysplastic syndromes (MDS) and chronic myeloproliferative disorders (CMD), which are precursors related to hematologic cancers, showed that they occurred more frequently among men than women in New Jersey. The age-adjusted incidence rate for MDS and CMD combined during 2008-2012 was 10.9 per 100,000 in men and 6.5 per 100,000 in women. White men had higher incidence of MDS compared to any other racial group/ethnicity (Table 11).

Cancers diagnosed at an early stage (in situ and local) have better treatment outcomes and better survival. For screenable cancers among New Jersey men diagnosed during 2008-2012, 89% of melanomas of the skin, 83% of prostate cancers, 41% of colorectal cancers and 17% of lung cancers were diagnosed at an early stage (Table 12). Among New Jersey women during this same time period, 91% of melanomas of the skin, 71% of breast cancers, 43% of cervical cancers, 40% of colorectal cancers and 21% of lung cancers were diagnosed at an early stage (Table 13). Black men had lower percentages of early-stage diagnoses compared to white men for all cancer sites presented. Black women had lower percentages of early-stage diagnoses for breast, cervical, and lung cancers but a higher percentage of early-stage diagnoses for colorectal cancer compared to white women. API men had a lower percentage of early-stage diagnoses for prostate cancer compared to other men. API women had lower percentages of early-stage diagnoses for colorectal cancer and melanoma compared to the other groups. Hispanic men had a lower percentage of early-stage diagnoses for melanoma compared to the New Jersey male population and a higher percentage of early-stage diagnoses for prostate cancer. Hispanic women had lower percentages of early-stage diagnoses for breast cancer and melanoma but higher percentages of early-stage diagnoses for cervical and colorectal cancers compared to the general female population (Tables 12 and 13).

Cancer Incidence in New Jersey and U.S. 2008-2012

Comparing New Jersey and U.S. age-adjusted incidence rates using data published in *Cancer in* North America by the North American Association of Central Cancer Registries (NAACCR) for 2008-2012, New Jersey incidence rates for all cancers combined continued to be higher than the U.S. rates, except for rates among black and API men and API women (Tables 14 and 15). Both New Jersey men and women had higher incidence rates compared to the U.S. for the most common cancers with some exceptions. New Jersey lung cancer incidence rates for men and women of all races combined, as well as white, black and API men and black and API women, were lower than the corresponding U.S. rates. New Jersey colorectal cancer incidence rates for black and API men and API women were lower than the U.S. rates, while rates for New Jersey black women were similar to the corresponding U.S. rates. New Jersey female breast cancer incidence rates were lower than the U.S. rates for black and API women, as well as New Jersey thyroid cancer incidence rates for black women. New Jersey melanoma incidence rates for black men and API women were lower than the U.S. rates, while New Jersey black and Hispanic women and Hispanic men had melanoma rates similar to the U.S. rates. New Jersey API men and women also had lower bladder cancer and non-Hodgkin lymphoma incidence rates compared to the U.S. rates, as well as lower rates of endometrial cancer (females). (Tables 14 and 15).

Cancer Mortality, New Jersey 2008-2012

Among New Jersey residents, a total of 16,483 deaths occurred in 2012 for which cancer was designated on the death certificate as the underlying cause, a slight decline compared to 16,708 reported cancer deaths in 2011. During the five-year time period 2008-2012, a total of 83,420 cancer deaths occurred among New Jersey residents, 49.3% among men and 50.7% among women. Primary cancers with the highest age-adjusted mortality rates for 2008-2012 in New Jersey were lung, prostate, and colon and rectum for men; and lung, breast, and colon and rectum for women. These cancers accounted for 45.7% and 49.3% of the total cancer deaths for men and women, respectively. Overall age-adjusted cancer mortality rates for men and women in New Jersey continued to decline (Table 16 and 17), reflecting the trends seen in U.S. mortality data (Howlader et al., 2015).

New Jersey cancer mortality rates continued to be higher for men than for women during 2008-2012 (199.0 per 100,000 versus 147.4 per 100,000). This pattern was observed among all races and ethnicity groups. Cancer mortality rates, including all sites, colorectal, prostate, and female breast, for both black men and women continued to be higher compared to white men and women with a few exceptions. Black men also had higher lung cancer mortality rates but lower lymphoma, leukemia, melanoma, bladder and brain cancer mortality rates compared to white men. Black women had lower lymphoma, leukemia, lung and brain cancer mortality rates than white women (Tables 18-21). Overall cancer mortality rates, as well as mortality rates for many common cancers, for New Jersey Hispanic men and women were lower than rates for all New Jersey men and women, except for slightly higher mortality rates for liver, stomach and cervical cancer (Table 22). New Jersey Asians and Pacific Islanders had much lower total cancer mortality rates than for the New Jersey total population, as well as lower female breast, colorectal, lung, and prostate cancer rates. However, stomach cancer mortality rates for API women were higher than in the New Jersey female general population (Table 23).

Cancer Mortality in New Jersey and U.S. 2008-2012

Comparing New Jersey and U.S. age-adjusted mortality rates for men during 2008-2012, New Jersey cancer mortality rates for all cancers, lung, and prostate cancer were lower than the corresponding rates for the U.S. for all men and in each racial/ethnic group, with the exception of prostate cancer mortality rates for New Jersey black men. New Jersey colorectal cancer mortality rates for all men, white men, and black men were slightly higher compared to the U.S. rates. Among all New Jersey women during the same time period, the cancer mortality rates for all cancers, breast and colorectal cancers were higher compared to the U.S. mortality rates. New Jersey total cancer mortality rates were higher than the corresponding U.S. rates for white women, but lower for black, API, and Hispanic women. New Jersey women had lower lung cancer mortality rates than U.S. women, and this pattern was observed for women of all racial/ethnic groups. The breast cancer mortality rate for New Jersey white women was higher than the U.S. rate, while New Jersey API and Hispanic women had lower breast cancer mortality rates. New Jersey colorectal cancer mortality rates were higher for white women than the corresponding U.S. rates, but lower for API and Hispanic women. New Jersey black women had colorectal cancer mortality rates similar to U.S. black women (Tables 24 and 25).

TECHNICAL NOTES

New Jersey State Cancer Registry (NJSCR)

NJSCR Overview

The objectives of the NJSCR are to:

- Monitor cancer trends in New Jersey
- Promote scientific research
- Educate the public
- Provide information for planning and evaluating cancer prevention and control activities
- Share and compare cancer data with other states and the nation
- Participate in population-based investigations of cancer etiology, prevention, treatment and outcomes

The NJSCR is a population-based cancer incidence registry that serves the entire state of New Jersey, which has a current estimated population of over 8.9 million people (U.S. Census Bureau). The NJSCR was established by legislation (N.J.S.A. 26:2-104 et seq.) and includes all cases of cancer diagnosed in New Jersey residents since October 1, 1978. New Jersey regulations (N.J.A.C. 8:57A) require the reporting of all newly diagnosed cancer cases to the NJSCR within three months of hospital discharge or six months of diagnosis, whichever is sooner. Reports are filed by hospitals, diagnosing physicians, dentists, and independent clinical laboratories. Every hospital in New Jersey reports cancer cases electronically. In addition, the NJSCR maintains reporting agreements with New York, Pennsylvania, and other surrounding states, as well as other state cancer registries that are enrolled in the North American Association of Central Cancer Registries (NAACCR) interstate data exchange program so that New Jersey residents diagnosed with cancer outside the state can be identified. Legislation passed in 1996 strengthened the NJSCR by requiring electronic reporting, requiring abstracting by certified tumor registrars, and establishing penalties for late or incomplete reporting.

All primary invasive and *in situ* neoplasms are reportable to the NJSCR, except cervical cancer *in situ* diagnosed after 1994 and certain carcinomas of the skin. Benign and borderline brain tumors diagnosed on or after January 1, 2004 are reportable according to Public Law 107-260, the Benign Brain Tumor Cancer Registries Act, which was signed in October 2002. The information collected by the NJSCR includes basic patient identifiers, demographic characteristics of the patient, medical information on each cancer diagnosis (such as the anatomic site, histologic type and stage of disease), first course of treatment and vital status (alive or deceased) annually. For deceased cases, the underlying cause of death is also included. The primary site, behavior, grade, and histology of each cancer are coded according to the *International Classification of Diseases for Oncology (ICD-O), 3rd edition* for cancers diagnosed after 2000. The NJSCR follows the data standards promulgated by the NAACCR, including the use of the Surveillance, Epidemiology, and End Results (SEER) multiple primary rules. An individual may develop more than one cancer. Following the SEER multiple primary rules, patients could therefore be counted more than once if they were diagnosed with two or more primary cancers.

The NJSCR is a member of the NAACCR, an organization that sets standards for cancer registries, facilitates data exchange, and publishes cancer data. The NJSCR has been a participant of the National Program of Cancer Registries (NPCR) sponsored by the Centers for Disease Control and Prevention (CDC) since it began in 1994 and is a member of the National Cancer Institute's (NCI) SEER Program.

NJSCR Data Quality

NAACCR has awarded the Gold Standard, the highest standard possible, to the NJSCR for the quality of the data for each diagnosis year 1995 through 2010 and 2012 and the Silver Standard for the 2011 diagnosis year. The NJSCR has consistently achieved the highest level of certification for its data since the inception of this award. The criteria used to judge the quality of the data are completeness of cancer case ascertainment, completeness of certain information on the cancer cases, percent of death certificate-only cases, percent of duplicate cases, passing an editing program, and timeliness.

Completeness of reporting to the NJSCR was estimated by comparing New Jersey and U.S. incidence to mortality rate ratios for whites and blacks, standardized for age, gender, and cancer site. The data used to generate these ratios were the cancer incidence rates for all SEER registries combined. Using these standard formulas, it is possible for the estimation of completeness to be greater than 100 percent. For 2012 data, the completeness of case reporting was estimated as 105 percent at the time this report was prepared.

While our estimates of completeness are very high, some cases of cancer among New Jersey residents who were diagnosed and/or treated in out-of-state facilities may not yet have been reported to the NJSCR by other state registries. This should be considered in interpreting the data for the more recent years. However, these relatively few cases will not significantly affect the overall trends over the time period presented in this report. The most recent year of data, in this case 2012, may be considered preliminary.

Other 2012 cancer incidence data quality indicators measured as follows:

- percent death-certificate-only cases: 1.6%
- percent of unresolved duplicates: < 0.1%
- percent of cases with unknown race: 1.3%
- percent of cases with unknown county: 0.03%
- number of cases with unknown age: 4
- number of cases with unknown gender: 8

It should also be noted that there may be minor differences in the New Jersey incidence and mortality rates in this report compared to previous reports, due to delayed reporting, ongoing editing and reviewing of the data. We also included myelodysplastic syndrome (MDS) and chronic myeloproliferative disorder (CMD) malignancies in the "All Sites" and "Ill-Defined & Unspecified Sites" categories, which made these rates higher than in reports published in 2012 or earlier, which did not include cases of MDS or CMD. Changes in the estimated population denominators also affect the incidence rates in this report and on our cancer mapping website compared to the previous years' publication.

The NJSCR continues to work toward improving the timeliness, quality, and number of its reporting sources. The NJSCR offers electronic reporting options for ambulatory care providers, such as: physician offices, radiation therapy centers, and freestanding surgery centers. In the past few years, the NJSCR has participated in two quality improvement projects to increase provider reporting. A targeted outreach to dermatologists and dermatology groups enhanced reporting of melanoma and other skin cancers. Reporting by independent radiation therapy centers improved the number of prostate and urological malignancy reports from urology specialists and radiation oncologists.

NJSCR has also made significant headway in identifying incident cases in a timely manner by increasing the number of facilities that use electronic pathology laboratory case identification. Currently, several hospital-based laboratories use the Artificial Intelligence in Medicine (AIM) electronic reporting software (E-Path) to automate cancer case identification for hospital tumor registry programs. NJSCR also uses E-Path to identify cancer reports from national pathology laboratories. One significant use of E-Path by a national laboratory ultimately increased the identification of hematological malignancies for the reporting period. The ultimate goal is to enable electronic pathology laboratory reporting from every laboratory that serves New Jersey, because it is evident that electronic pathology cancer identification has improved the timeliness and completeness of cancer reporting, especially for non-hospitalized case reports. Trends in future reporting are driving the NJSCR to develop appropriate systems to identify and receive HL7 messages, as well as to accept Meaningful Use data upon the implementation phase for cancer reporting.

One limitation that could affect New Jersey cancer incidence data is the federal formal restrictions on the submission of cancer cases from Veterans Health Administration (VA) hospitals to cancer registries. NJSCR received 0.6% of the total cases exclusively from VA hospitals for the years 2004 and earlier. Since then, the NJSCR received only 0.3% of the total cases from VA hospitals for 2005 and no cases for 2006 through 2012. The impact of missing VA hospital cases in New Jersey could result in underestimates of cancer incidence rates for men in 2008 through 2012. NJSCR is exploring the possibility of receiving electronic VA cases through a secure file transfer source.

Data Sources and Specifications

Incidence Data

New Jersey cancer incidence data were taken from the January 2015 analytic file of the NJSCR. All the counts and rates were tabulated using SEER*Stat Version 8.1.5 (http://www.seer.cancer.gov/seerstat/), a statistical software package distributed by the NCI. U.S. cancer incidence data were obtained from NAACCR's publication, *Cancer in North America* 2008-2012 (http://www.naaccr.org/DataandPublications/CINAPubs.aspx).

The cancer categories in this report are based on the primary site and histology data fields as abstracted from the medical records. For detailed definitions of the cancer categories, please visit the SEER program website (http://www.seer.cancer.gov/siterecode/icdo3_d01272003/). We used the cancer site recode with mesothelioma and Kaposi sarcoma in separate categories in all incidence tables except for the benign and borderline brain tumor table.

Benign and borderline brain tumors are classified into six groups by primary site: brain, intracranial meninges, cranial nerves and other central nervous system, tumor of the sellar region (pituitary gland, craniopharyngeal duct, and pineal gland), spinal cord, and spinal meninges.

The coding scheme for incident cancer cases in this report is derived from *International Classification of Diseases for Oncology, 3rd edition (ICD-O-3)*. Cases included in the rate tables are all invasive cancers in ICD-O-3 except the benign and borderline brain tumor table. There are some reportability changes from ICD-O-2 to ICD-O-3 beginning in 2001. Myelodysplastic syndrome (MDS) (9980, 9982-9987, 9989) and chronic myeloproliferative disorder (CMD) (9950, 9960-9962) were defined as malignant in ICD-O-3. In previous reports published before 2013, we had only included cases that were reportable in ICD-O-2 and ICD-O-3 to ensure the comparability of rates. Because these cancers were reportable for the entire time period covered by this report, MDS and CMD are included in the rate tables for "All Sites" and in "Ill-Defined & Unspecified Sites" categories. The "All Sites" rates are higher than in the previous report tables published before 2013 because of the inclusion of these additional types of cancer.

Caution must be used when looking at statistics over time for total cancers or categories that include tumors with revised behavior. In this report, data presented for the most recent five years, 2008-2012, include cancers classified as malignant based on ICD-O-3, which is the current standard. However, for any time trends where incidence rates are displayed by year from 1979 to 2012, the practice followed by the National Cancer Institute should be used, excluding most newly-reportable cancers as well as the tumors that are no longer classified as malignant, for consistency purposes. The SEER program provides more detailed explanations (see http://www.seer.cancer.gov/behavrecode/).

Exclusions

For this report, cases where the county of residence is unknown were excluded from the New Jersey rates and counts, in accordance with standard procedures used by SEER, and has been determined to have little effect on the incidence rates. For example, the total number of cases with unknown county for 2008-2012 is 232, representing 0.1% of the total cancer cases. The small numbers of cases with unknown age or gender were also excluded from the analyses. Since the number of records affected was very small, the rates were virtually unaffected by the exclusion of these records. Race-specific information is not shown separately for persons who are races other than white, black, or Asian and Pacific Islander, but these persons and persons of unknown race are included in the "all races" data.

Mortality Data

New Jersey and U.S. cancer mortality data for 2008-2012 were obtained through the NCI SEER Program from the National Center for Health Statistics (NCHS) and tabulated using SEER*Stat Version 8.2.1 (http://www.seer.cancer.gov/seerstat/).

Mortality data were grouped by cancer site according to the revised SEER Cause of Death Recode 1969+ (9/17/2004). The detailed information can be found on the SEER website (http://seer.cancer.gov/codrecode/).

Population Data

The 2008-2012 New Jersey population estimates for this report were provided by the NCI's SEER Program released in January 2015 and downloaded from the SEER website (http://www.seer.cancer.gov/popdata/download.html). The population estimates represent a modification of the intercensal and Vintage 2013 annual time series of July 1 county population estimates by age, sex, race, and Hispanic origin produced by the US Census Bureau's Population Estimates Program, in collaboration with the National Center for Health Statistics, and with support from the NCI through an interagency agreement. The bridged single-race estimates and a description of the methodology used to develop them are available on the National Center for Health Statistics (NCHS) website (http://www.cdc.gov/nchs/nvss/bridged_race.htm).

Description of Algorithm for Designating Hispanic Ethnicity

In 2003, the NJSCR adopted the NAACCR Hispanic Identification Algorithm (NHIA) to assign Hispanic ethnicity to cases. This method uses data on birthplace, marital status, gender, race and surname match to the 1990 Hispanic surname list to augment the number of cases and decedents reported as Hispanic in the registry.

Since 2005, NAACCR made several revisions to the NHIA algorithm, now NHIA version 2. The most significant change in NHIA version 2 was the two additional options for registries to apply the algorithm to counties in which the Hispanic population is less than five percent. The NJSCR applied the algorithm to all records from patients residing in all New Jersey counties (option 0 of the NHIA algorithm) diagnosed during the years 1990-2012.

As a result of applying the NHIA algorithm, the number of cases who were coded as Hispanic increased by 22 percent for this time period, thereby correcting an under-identification of Hispanics. A more complete description of the NHIA version 2 is available at the following link to the NAACCR website:

http://www.naaccr.org/LinkClick.aspx?fileticket=6E20OT41TcA%3d&tabid=118&mid=458. For a copy of the NHIA SAS program, please see the NHAPIIA SAS Code and Related Files section on the following link to the NAACCR website:

 $\underline{http://www.naaccr.org/Data and Publications/Callfor Data.aspx}.$

Caution should be used when comparing rates among Hispanics with the rates in the different race groups (e.g., black, white) because ethnicity and race are not mutually exclusive. In New Jersey, the majority of Hispanics identify themselves as white. The Hispanics who identify themselves as white, black, or API are included in the white, black, or API race category, as well as the 'all races' category.

Caution should also be used when comparing Hispanic mortality data to Hispanic incidence data in this report. Hispanic mortality data for this report were obtained from NCI's SEER Program and did not have the algorithm applied to them. In our detailed report, *Cancer Among Hispanics in New Jersey*, 1990-1996, our previous Hispanic algorithm was applied to mortality

data from the New Jersey Center for Health Statistics, resulting in an increased mortality rate of 13% for men and 23% for women.

Race

Race information in the NJSCR database is collected from medical records and is not always complete and accurate. The impact of missing race for a relatively small proportion of cases results in slightly lower race-specific cancer incidence rates and counts. A small percentage of cases diagnosed in previous years were reported to the NJSCR with missing information on race at the time of the completion of last year's report, *Cancer Incidence and Mortality in New Jersey 2007-2011*, and later had their race updated after the publication of the report. This resulted in a slight increase in the race-specific cancer incidence rates and counts during 2008-2011 in the current report as compared to previous reports.

Asians and Pacific Islanders

Asians and Pacific Islanders account for only 3.5% of the total cancer cases in New Jersey, and missing race or misclassification of race may have a relatively greater effect on API cancer rates than rates for other racial groups. For total cancer cases diagnosed during 2008-2012, 1.5% were reported to be of other or unknown race. The NJSCR applied the NAACCR Asian Pacific Islander Identification Algorithm version 1 (NAPIIA v1.2.1) using the birthplace and name fields (first, last, and maiden names) to classify cases directly or indirectly as Asian/Pacific Islander for analytic purposes. The NAPIIA algorithm is focused on coding cases with a race code of other Asian or other Pacific Islander to a more specific Asian or Pacific Islander race category, and the total API case count did not change after applying the algorithm.

Data Presentation

Suppression of Rates and Counts under Five

It should also be noted that the annual rates for relatively uncommon cancers tend to fluctuate substantially from year to year because of small numbers of cases, particularly in minority populations. Rates generated from small numbers should be interpreted with caution. For this report, incidence rates and counts were suppressed where counts were fewer than five as a way to ensure statistical reliability and patient confidentiality. The mortality data were provided through NCI's SEER program in the SEER*Stat database and the data were suppressed by default where counts were fewer than ten.

Calculation of Rates

All the counts and rates were tabulated using SEER*Stat Version 8.2.1 (http://www.seer.cancer.gov/seerstat/), a statistical software package distributed by the National Cancer Institute. U.S. cancer incidence data were obtained from NAACCR's publication, *Cancer in North America* 2008-2012

(<u>http://www.naaccr.org/DataandPublications/CINAPubs.aspx</u>). All rates are age-adjusted to the 2000 U.S. Standard Population (19 age groups-Census P25-1130).

Rate Calculation Formulas

A cancer incidence rate is defined as the number of new cases of cancer detected during a specified time period in a specified population. Cancer rates are most commonly expressed as cases per 100,000 population. Cancer occurs at different rates in different age groups, and population subgroups defined by gender and race have different age distributions. Therefore, before a valid comparison can be made between rates, it is necessary to standardize the rates to the age distribution of a standard population.

The first step in the age-standardization procedure is to determine the age-specific rates. For each age group for a given time interval (within each race-gender group, for the entire state), the following formula is applied:

$$r_a = \frac{n_a}{t \times P_a}$$

where

 $r_a = the age-specific rate for age group a,$

 $n_a =$ the number of events (cancer diagnoses) in the age group during the time interval,

t = the length of the time interval (in years), and

P_a = average size of the population in the age group during the time interval (mid-year population or average of mid-year population sizes).

In order to determine the age-adjusted rate, a weighted average of the age-specific rates is calculated, using the age distribution of the standard population to derive the age-specific weighting factors (Rothman, 1986). This is the technique of direct standardization which uses the following formula:

$$R = \frac{\sum_{a=1}^{n} r_a \times Std. P_a}{\sum_{a=1}^{n} Std. P_a}$$

where

R =the age-adjusted rate,

 r_a = the age-specific rate for age group a, and

Std.P_a = the size of the standard population in each age group a.

While age standardization facilitates the comparison of rates among different populations, there can be important age-specific differences in disease occurrence, which are not apparent in comparisons of the age-adjusted rates (Breslow and Day, 1987).

Analogous definitions and calculations apply for cancer mortality rates.

REFERENCES

Breslow NE, Day NE. Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies. New York: Oxford University Press, 1987.

Centers for Disease Control and Prevention. *Data collection of primary central nervous system tumors. National Program of Cancer Registries Training Materials.* Atlanta, Georgia: Department of Health and Human Services, Centers for Disease Control and Prevention, 2004.

Copeland G, Lake A, Firth R, et al. (eds). *Cancer in North America:* 2008-2012. Springfield, IL: North American Association of Central Cancer Registries, Inc. June 2015, [URL: http://www.naaccr.org/DataandPublications/CINAPubs.aspx, accessed June 11, 2015].

Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015.

Ingram DD, Parker JD, Schenker N, et al. United States Census 2000 population with bridged race categories. National Center for Health Statistics. Vital Health Stat 2(135). 2003. [URL. http://www.cdc.gov/nchs/data/series/sr_02/sr02_135.pdf, accessed June 11, 2015].

Martin RM. "Age standardization of death rates in New Jersey: Implications of a change in the standard population." Topics in Health Statistics. Center for Health Statistics. 2000;01-02.

NAACCR Race and Ethnicity Work Group. *NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2.2.1]*. Springfield (IL): North American Association of Central Cancer Registries. September 2011. [URL:

http://www.naaccr.org/LinkClick.aspx?fileticket=6E20OT41TcA%3d&tabid=118&mid=458, accessed June 11, 2015].

NAACCR Race and Ethnicity Work Group. *NAACCR Asian Pacific Islander Identification Algorithm [NAPIIA v1.2.1]*. Springfield, IL: North American Association of Central Cancer Registries, August 2011. [URL:

http://www.naaccr.org/LinkClick.aspx?fileticket=3HnBhlmhkBs%3d&tabid=92&mid=432, accessed June 11, 2015].

National Center for Health Statistics. U.S. census population with bridged race categories, August 2008. [URL. http://www.cdc.gov/nchs/nvss/bridged_race.htm, accessed June 11, 2015].

Rothman K. Modern Epidemiology. U.S. Little, Brown, and Company. 1986.

Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 8.1.15. March 31, 2014.

Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 8.2.1. April 7, 2015.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1990-2012) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released Apirl 2015. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Populations - Total U.S. (1969-2012) <Katrina/Rita Adjustment> - Linked To County Attributes - Total U.S., 1969-2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released March 2014. [URL. http://seer.cancer.gov/popdata/, accessed January 2015].

U.S. Census Bureau. New Jersey QuickFacts from the U.S. Census Bureau. [URL: http://quickfacts.census.gov/qfd/states/34000.html, accessed 3/18/2015].

Weinstein R, Lee YS, Klotz J. *Cancer Among Hispanics in New Jersey 1990-1996*. New Jersey Department of Health and Senior Services, June 2000. [URL. http://www.state.nj.us/health/cancer/hispanic/, accessed June 11, 2015].

Incidence Tables

Table 1. Age-adjusted Incidence Rates, Males, All Races Combined

			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012 Prelim.	2008	-2012
All Sites*	590.7	583.6	561.6	559.0	528.2	122,793	564.0
Oral Cavity and Pharynx	14.4	15.8	15.3	14.6	14.8	3,458	15.0
Lip	0.5	0.8	0.5	0.6	0.5	120	0.6
Tongue	4.6	5.2	4.5	4.6	5.1	1,118	4.8
Salivary Gland	2.0	1.8	2.0	1.8	1.8	386	
Floor of Mouth	0.6	0.6	0.8	0.4	0.5	146	
Gum and Other Mouth	1.9	1.5	1.5	1.8	1.7	373	
Nasopharynx	0.7	1.0	0.9	0.8	0.9	194	0.9
Tonsil	2.1	3.0	3.2	2.6	2.5	656	
Oropharynx	0.7	0.6	0.9	0.7	0.7	166	
Hypopharynx	1.1	1.1	0.9	1.0	1.0	236	
Digestive System	111.0	109.4	104.3	101.3	100.3	22,753	105.2
Esophagus	8.1	7.9	8.8	7.8	7.6	1,765	8.1
Stomach	11.2	11.8	11.6	10.5	10.8	2,365	11.2
Small Intestine	2.8	2.9	1.7	2.6	2.5	544	2.5
Colon and Rectum	56.6	53.7	49.5	47.7	47.2	10,891	50.9
Colon excluding Rectum	39.4	37.1	33.7	32.4	31.6	7,341	34.8
Rectum and Rectosigmoid Junction	17.2	16.6	15.9	15.3	15.6	3,550	
Anus, Anal Canal and Anorectum	1.7	1.4	1.6	1.3	1.2	321	1.4
Liver and Intrahepatic Bile Duct	10.4	11.3	10.7	11.6	11.3	2,564	11.1
Liver	9.9	10.6	9.6	10.4	10.1	2,360	10.1
Intrahepatic Bile Duct	0.5	0.7	1.1	1.2	1.1	204	0.9
Gallbladder	1.0	0.9	1.1	1.1	1.2	218	1.1
Other Biliary	2.5	2.8	2.4	2.7	2.4	539	
Pancreas	15.5	15.7	15.7	14.9	14.9	3,301	15.3
Respiratory System	81.7	79.5	75.3	73.9	71.8	16,156	76.3
Larynx	5.9	6.5	6.0	5.7	5.0	1,286	
Lung and Bronchus	74.2	71.8	68.2	67.1	65.4	14,600	
Bones and Joints	1.0	1.2	1.3	1.2	1.4	261	1.2
Soft Tissue (Including Heart)	4.5	4.3	4.5	4.0	4.2	919	4.3
Skin (Excluding Basal and Squamous)	30.3	30.1	29.8	30.8	29.9	6,520	30.2
Melanoma of the Skin	28.3	27.2	27.8	28.6	27.5	6,044	

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 1 (continued). Age-adjusted Incidence Rates, Males, All Races Combined

			Rates		Cases Rates			
Cancer Site	2008	2009	2010	2011	2012 Prelim.	2008-	2012	
Breast	1.6	1.2	1.7	1.4	1.5	316	1.5	
Male Genital System	176.5	173.9	161.9	171.9	137.6	37,065	164.0	
Prostate	170.2	167.1	155.3	164.6	130.9	35,641	157.2	
Testis	5.3	6.0	5.8	6.1	5.6	1,210	5.8	
Penis	0.8	0.7	0.5	1.0	0.9	166	0.8	
Urinary System	68.4	66.2	64.2	63.2	65.2	13,835	65.4	
Urinary Bladder (Including in situ)	44.2	42.1	41.4	40.5	42.1	8,652	42.0	
Kidney and Renal Pelvis	22.3	22.8	20.9	21.3	21.4	4,852	21.7	
Ureter	1.0	0.7	1.2	1.0	0.9	199	1.0	
Eye and Orbit	1.0	0.7	0.4	0.7	1.0	165	0.8	
Brain and Other Nervous System	8.8	8.6	8.7	7.8	8.8	1,851	8.6	
Brain	8.1	8.1	8.0	7.2	8.3	1,723	8.0	
Endocrine System	9.6	10.0	10.2	10.9	11.0	2,323	10.4	
Thyroid	8.3	9.1	9.2	10.0	10.2	2,105	9.4	
Lymphomas	29.7	29.5	28.6	27.8	29.7	6,224	29.0	
Hodgkin Lymphoma	3.6	4.1	3.8	3.3	3.8	794	3.7	
Non-Hodgkin Lymphoma	26.1	25.4	24.8	24.5	25.9	5,430	25.3	
Myelomas	8.3	9.1	8.4	7.8	8.6	1,804	8.4	
Leukemias	17.3	17.3	20.3	18.6	18.8	3,931	18.5	
Lymphocytic Leukemia	9.3	9.0	11.0	9.8	10.2	2,115	9.9	
Acute Lymphocytic Leukemia	1.7	1.9	2.3	1.7	1.8	393	1.9	
Chronic Lymphocytic Leukemia	6.8	6.6	7.9	7.3	7.5	1,545	7.2	
Myeloid and Monocytic Leukemia	7.1	7.2	8.2	8.0	7.8	1,624	7.7	
Acute Myeloid Leukemia	4.2	4.1	5.5	5.2	5.3	1,022	4.9	
Acute Monocytic Leukemia	0.4	0.4	0.3	0.3	0.2	73	0.3	
Chronic Myeloid Leukemia	2.3	2.4	2.1	2.0	2.0	465	2.2	
Other Leukemia	0.9	1.0	1.1	0.8	0.8	192	0.9	
Mesothelioma	2.8	3.0	2.9	2.4	2.0	519	2.6	
Kaposi Sarcoma	0.7	0.9	0.7	0.6	0.6	146	0.7	
III-Defined & Unspecified Sites*	23.2	22.8	23.1	20.1	21.3	4,547	22.1	

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 2. Age-adjusted Incidence Rates, Females, All Races Combined

		Rates		Cases	Rates		
Cancer Site	2008	2009	2010	2011	2012 Prelim.	2008	-2012
All Sites*	457.9	458.2	447.0	442.6	444.6	121,739	449.9
Oral Cavity and Pharynx	6.2	6.6	5.6	6.3	6.1	1,663	6.1
Lip	0.3	0.3	0.2	0.3	0.2	79	0.3
Tongue	1.8	1.8	1.5	1.7	1.9	478	1.8
Salivary Gland	1.2	1.1	1.0	1.1	1.2	301	1.1
Floor of Mouth	0.3	0.4	0.4	0.4	0.2	98	0.4
Gum and Other Mouth	1.2	1.4	1.1	1.3	1.3	340	1.2
Nasopharynx	0.3	0.3	0.4	0.4	0.3	86	0.3
Tonsil	0.5	0.6	0.4	0.6	0.7	146	
Oropharynx	0.3	0.2	0.2	0.2	0.1	58	0.2
Hypopharynx	0.1	0.2	0.3	0.3	0.2	59	0.2
Digestive System	72.8	72.2	70.1	70.9	70.2	20,139	71.2
Esophagus	2.1	2.0	2.0	1.7	2.1	567	2.0
Stomach	5.9	5.6	5.9	5.6	5.6	1,613	5.7
Small Intestine	2.1	2.0	1.7	1.9	1.9	530	
Colon and Rectum	40.8	39.8	39.0	38.7	38.5	11,149	39.3
Colon excluding Rectum	30.7	28.9	29.4	29.0	27.5	8,309	29.1
Rectum and Rectosigmoid Junction	10.1	10.8	9.7	9.7	11.0	2,840	10.3
Anus, Anal Canal and Anorectum	2.1	2.1	1.8	2.0	2.2	555	2.0
Liver and Intrahepatic Bile Duct	3.3	3.7	3.7	3.2	3.9	993	3.6
Liver	2.9	3.1	2.7	2.4	3.2	801	2.9
Intrahepatic Bile Duct	0.4	0.6	0.9	0.8	0.6	192	0.7
Gallbladder	1.7	1.8	1.8	1.6	1.5	471	1.7
Other Biliary	1.2	1.4	1.3	1.5	1.5	403	1.4
Pancreas	11.8	12.2	11.4	12.9	11.7	3,411	12.0
Respiratory System	60.3	57.5	53.8	55.8	51.5	15,455	55.7
Larynx	1.5	1.4	1.4	1.3	1.3	376	1.4
Lung and Bronchus	58.1	55.3	51.9	53.8	49.7	14,901	53.7
Bones and Joints	1.0	1.0	1.0	0.9	0.7	213	0.9
Soft Tissue (Including Heart)	2.8	3.2	3.0	2.9	3.2	776	3.0
_							
Skin (Excluding Basal and Squamous)	18.0	17.9	18.9	17.0	18.8	4,754	
Melanoma of the Skin	16.8	16.7	17.9	15.6	17.2	4,404	16.9
Breast (Invasive)	131.5	133.2	129.1	127.2	129.7	34,776	
In situ (not included in All Sites)	41.8	41.3	41.6	40.5	40.5	10,790	41.1

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 2 (continued). Age-adjusted Incidence Rates, Females, All Races Combined

			Rates			Cases Rates		
Cancer Site	2008	2009	2010	2011	2012		-2012	
					Prelim.			
Female Genital System	55.6	56.5	56.5	53.7	54.7	14,983	55.4	
Cervix Uteri	8.1	8.7	8.2	7.7	7.1	1,957	8.0	
Corpus and Uterus, NOS	29.6	30.7	30.3	29.5	30.9	8,338	30.2	
Corpus Uteri	28.6	29.7	29.4	28.5	29.8	8,059	29.2	
Uterus, NOS	1.0	1.0	0.9	1.0	1.1	279	1.0	
Ovary	13.7	12.9	13.6	12.8	12.1	3,513	13.0	
Vagina	0.7	0.5	0.7	0.7	0.9	192	0.7	
Vulva	2.5	2.6	2.6	2.2	2.7	713	2.5	
Urinary System	24.0	22.9	21.1	20.6	22.6	6,165	22.2	
Urinary Bladder (Including in situ)	12.1	11.7	11.1	10.4	11.1	3,187	11.2	
Kidney and Renal Pelvis	11.3	10.7	9.3	9.5	10.9	2,792	10.4	
Ureter	0.4	0.5	0.4	0.5	0.4	125	0.4	
Eye and Orbit	0.4	0.5	0.4	0.4	0.6	117	0.5	
Brain and Other Nervous System	5.9	5.7	6.0	5.4	5.6	1,435	5.7	
Brain	5.3	5.1	5.5	4.9	5.2	1,315	5.2	
Endocrine System	25.2	29.2	28.2	27.6	28.5	6,682	27.7	
Thyroid	24.5	28.2	27.3	27.0	27.7	6,488	26.9	
Lymphomas	21.6	20.8	20.6	21.6	19.9	5,556	20.9	
Hodgkin Lymphoma	3.5	2.9	2.7	3.3	2.8	684	3.0	
Non-Hodgkin Lymphoma	18.2	17.9	17.9	18.3	17.0	4,872	17.9	
Myelomas	5.4	5.4	5.8	5.4	5.6	1,535	5.5	
Leukemias	10.5	10.4	11.0	11.9	11.5	2,944	11.0	
Lymphocytic Leukemia	4.3	5.1	5.7	5.6	5.7	1,417	5.3	
Acute Lymphocytic Leukemia	1.3	1.3	1.3	1.6	1.5	300	1.4	
Chronic Lymphocytic Leukemia	2.8	3.6	4.1	3.7	3.9	1,042	3.6	
Myeloid and Monocytic Leukemia	5.5	4.7	4.8	5.4	5.2	1,353	5.1	
Acute Myeloid Leukemia	3.7	3.0	3.1	3.9	3.4	912	3.4	
Acute Monocytic Leukemia	0.2	0.2	0.2	0.2	0.2	52	0.2	
Chronic Myeloid Leukemia	1.4	1.3	1.5	1.1	1.4	349	1.3	
Other Leukemia	0.7	0.6	0.4	0.8	0.6	174	0.6	
Mesothelioma	0.8	0.4	0.5	0.6	0.4	158	0.6	
Kaposi Sarcoma	0.1	0.2	0.1	0.2	0.1	43	0.2	
Ill-Defined & Unspecified Sites*	15.8	14.9		14.2	14.9	4,345	15.0	

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 3. Age-adjusted Incidence Rates, White Males

	Rates						Cases Rates	
Cancer Site	2008	2009	2010	2011	2012 Prelim.	2008	-2012	
All Sites*	606.5	593.6	569.6	562.8	538.2	102,784	573.5	
Oral Cavity and Pharynx	14.8	16.3	15.9	15.1	15.2	2,917	15.5	
Lip	0.5	0.8	0.6	0.6	0.5	112	0.6	
Tongue	4.9	5.7	4.9	4.8	5.5	981	5.2	
Salivary Gland	2.0	1.9	2.1	1.9	2.0	341	2.0	
Floor of Mouth	0.7	0.6	0.8	0.5	0.5	122	0.6	
Gum and Other Mouth	1.7	1.3	1.3	1.6	1.5	278	1.5	
Nasopharynx	0.6	0.7	0.7	0.6	0.6	113	0.6	
Tonsil	2.3	3.3	3.5	3.0	2.7	589	3.0	
Oropharynx	0.7	0.6	0.8	0.8	0.7	134	0.7	
Hypopharynx	1.1	1.2	0.9	1.0	0.9	192	1.0	
Digestive System	110.6	107.8	101.9	100.6	100.8	18,669	104.3	
Esophagus	8.3	8.2	8.7	8.3	8.2	1,518		
Stomach	10.7	11.4	11.1	10.4	10.3	1,899	10.8	
Small Intestine	2.9	2.6	1.8	2.5	2.5	441	2.5	
Colon and Rectum	57.4	53.0	49.2		48.2	9,032		
Colon excluding Rectum	39.9	36.5	33.5		32.0	6,091	34.6	
Rectum and Rectosigmoid Junction	17.5	16.5	15.7	15.6	16.2	2,941	16.3	
Anus, Anal Canal and Anorectum	1.7	1.4	1.4	1.3	1.2	256		
Liver and Intrahepatic Bile Duct	9.3	10.8	9.6		10.7	1,924		
Liver	8.8	10.0	8.4	9.5	9.5	1,750		
Intrahepatic Bile Duct	0.5	0.8	1.2	1.2	1.2	174		
Gallbladder	0.9	0.9	1.1	1.1	1.1	176		
Other Biliary	2.7	2.8	2.4		2.5	464		
Pancreas	15.6	15.7	15.5	15.1	14.9	2,760	15.4	
Respiratory System	82.9	80.5	76.1	75.5	73.5	13,717	77.6	
Larynx	5.8	6.5	5.8	5.9	5.2	1,066	5.8	
Lung and Bronchus	75.5	72.7	69.3		66.9	12,431		
Bones and Joints	1.1	1.4	1.5	1.4	1.5	224	1.4	
Soft Tissue (Including Heart)	4.8	4.5	4.7	4.3	4.4	781	4.5	
Skin (Excluding Basal and Squamous)	35.7	35.1	34.5	35.4	34.6	6,237	35.1	
Melanoma of the Skin	33.5	32.2	32.4		32.0	,		

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

^{*}All ICD-O-3 invasive reportable cases are included.

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 3 (continued). Age-adjusted Incidence Rates, White Males

		Cases Rates					
Cancer Site	2008	2009	2010	2011	2012	2008-	2012
					Prelim.		
Breast	1.5	1.1	1.7	1.4	1.5	260	1.4
Male Genital System	175.5	170.1	156.4	161.9	130.6	29,351	158.5
Prostate	167.8	161.7	148.8	153.3	122.6	28,076	150.4
Testis	6.7	7.5	6.9	7.4	7.0	1,100	7.1
Penis	0.7	0.7	0.9	1.0	0.9	133	0.8
T Child	0.9	0.7	0.4	1.0	0.9	133	0.0
Urinary System	73.3	71.3	68.9	66.7	69.8	12,341	69.9
Urinary Bladder (Including <i>in situ</i>)	48.0	46.0	45.0	44.0	46.0	7,953	45.8
Kidney and Renal Pelvis	23.3	23.8	21.7	21.2	22.2	4,090	22.4
Ureter	1.1	0.8	1.5	1.1	0.9	188	1.1
	1.1	0.0	1.5	1.1	0.5	100	1.1
Eye and Orbit	1.2	0.8	0.5	0.8	1.1	153	0.9
Brain and Other Nervous System	9.8	9.5	9.5	8.4	9.7	1,608	9.4
Brain	9.0	9.0	8.8	7.8	9.2	1,506	8.8
	7.0	7.0	0.0	7.0	7.2	1,500	0.0
Endocrine System	10.4	10.8	11.2	12.0	12.0	1,995	11.3
Thyroid	9.1	9.9	10.2	11.1	11.3	1,824	10.3
Lymphomas	31.3	31.1	30.0	29.7	31.3	5,338	30.7
Hodgkin Lymphoma	3.7	4.4	3.9	3.6	4.1	644	3.9
Non-Hodgkin Lymphoma	27.6	26.7	26.1	26.1	27.2	4,694	26.7
Myelomas	7.7	8.6	7.8	7.2	8.1	1,403	7.9
Leukemias	18.3	18.0	21.3	18.7	19.1	3,317	19.1
Lymphocytic Leukemia	10.2	9.7	11.6	9.6	10.0	1,776	10.2
Acute Lymphocytic Leukemia	1.8	2.1	2.5	1.7	1.7	308	2.0
Chronic Lymphocytic Leukemia	7.4	7.0	8.2	7.1	7.2	1,317	7.4
Myeloid and Monocytic Leukemia	7.3	7.3	8.7	8.3	8.2	1,383	8.0
Acute Myeloid Leukemia	4.5	4.1	6.0	5.4	5.7	887	5.2
Acute Monocytic Leukemia	0.4	0.5	0.4	0.4	0.2	68	0.4
Chronic Myeloid Leukemia	2.2	2.4	2.1	2.0	2.0	374	2.1
Other Leukemia	0.9	1.0	1.1	0.8	0.8	158	0.9
Mesothelioma	3.2	3.3	3.1	2.6	2.2	490	2.9
Kaposi Sarcoma	0.7	0.7	0.6	0.4	0.4	94	0.6
·							
Ill-Defined & Unspecified Sites* Rates are per 100,000 population and age-adjusted to	23.7	22.7	23.6	20.5	22.2	3,889	22.5

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 4. Age-adjusted Incidence Rates, White Females

			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008-2012	
					Prelim.		
All Sites*	477.8	480.5	462.5	458.1	465.1	102,105	468.7
Oral Cavity and Pharynx	6.7	6.8	5.9	6.8	6.2	1,416	6.5
Lip	0.4	0.3	0.3	0.3	0.2	75	0.3
Tongue	2.1	2.0	1.6	2.0	2.0	415	1.9
Salivary Gland	1.2	1.2	1.2	1.1	1.2	253	1.2
Floor of Mouth	0.4	0.5	0.5	0.4	0.2	90	0.4
Gum and Other Mouth	1.3	1.4	1.2	1.4	1.2	289	1.3
Nasopharynx	0.3	0.3	0.2	0.3	0.3	58	0.3
Tonsil	0.5	0.6	0.5	0.6	0.7	128	0.6
Oropharynx	0.3	0.2	0.1	0.2	0.1	45	0.2
Hypopharynx	0.1	0.2	0.3	0.3	0.1	47	0.2
Digestive System	71.5	72.4	68.7	68.6	69.4	16,443	70.1
Esophagus	1.9	2.0	2.0	1.6	1.9	452	1.9
Stomach	5.4	5.0	5.3	4.8	5.3	1,202	5.1
Small Intestine	2.0	2.0	1.5	2.1	1.9	426	1.9
Colon and Rectum	40.6	40.6	38.6	37.7	38.5	9,222	39.2
Colon excluding Rectum	30.6	29.6	29.0	28.2	27.5	6,916	29.0
Rectum and Rectosigmoid Junction	10.0	10.9	9.6	9.5	11.0	2,306	10.2
Anus, Anal Canal and Anorectum	2.3	2.3	2.0	2.0	2.4	484	2.2
Liver and Intrahepatic Bile Duct	3.1	3.6	3.4	3.1	3.6	765	3.4
Liver	2.7	2.9	2.5	2.2	3.0	605	2.7
Intrahepatic Bile Duct	0.3	0.7	0.9	0.9	0.7	160	0.7
Gallbladder	1.6	1.8	1.7	1.4	1.3	368	1.6
Other Biliary	1.3	1.3	1.3	1.3	1.5	332	1.3
Pancreas	11.6	11.9	11.4	12.8	11.5	2,826	11.9
Respiratory System	63.1	60.5	56.1	59.7	54.6	13,412	58.8
Larynx	1.5	1.4	1.5	1.4	1.4	316	1.4
Lung and Bronchus	60.9	58.4	54.1	57.5	52.6		56.7
Bones and Joints	1.1	0.9	1.1	1.0	0.8	182	1.0
Soft Tissue (Including Heart)	2.8	3.3	3.1	2.8	3.2	616	3.0
Skin (Excluding Basal and Squamous)	21.9	21.7	22.9	20.1	22.6	4,514	21.8
Melanoma of the Skin	20.7	20.5	21.9	18.7	20.9	4,212	20.5
Breast (Invasive)	135.8	138.4	132.6	131.2	134.9	28,653	134.5
In situ (not included in All Sites)	44.2	44.5	43.4	41.1	43.0	8,873	43.2

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 4 (continued). Age-adjusted Incidence Rates, White Females

			Rates			Cases Rates		
Cancer Site	2008	2009	2010	2011	2012	2008		
					Prelim.			
Female Genital System	57.7	59.5	58.0	56.2	57.4	12,473	57.8	
Cervix Uteri	8.0	8.8	7.8	7.7	7.1	1,460	7.9	
Corpus and Uterus, NOS	31.2	32.5	31.3	31.0	33.1	7,048	31.8	
Corpus Uteri	30.4	31.6	30.6	30.2	32.1	6,862	31.0	
Uterus, NOS	0.8	0.9	0.7	0.7	0.9	186	0.8	
Ovary	14.2	13.9	14.3	13.6	12.5	2,960	13.7	
Vagina	0.6	0.4	0.7	0.7	0.8	144	0.6	
Vulva	2.7	2.8	2.8	2.4	2.8	634	2.7	
Urinary System	25.6	24.7	21.9	21.5	23.7	5,337	23.5	
Urinary Bladder (Including in situ)	13.2	12.9	11.8	11.2	11.9	2,859	12.2	
Kidney and Renal Pelvis	11.8	11.2	9.5	9.6	11.2	2,319	10.7	
Ureter	0.5	0.5	0.5	0.5	0.4	116	0.5	
Eye and Orbit	0.5	0.5	0.5	0.4	0.8	110	0.5	
Brain and Other Nervous System	6.6	5.9	6.6	6.0	6.4	1,243	6.3	
Brain	6.0	5.3	6.1	5.5	5.9	1,148	5.8	
Endocrine System	27.8	32.7	30.1	29.7	32.0	5,538	30.5	
Thyroid	27.2	31.8	29.4	29.1	31.0	5,398	29.7	
Lymphomas	23.7	21.9	22.3	22.7	21.3	4,786	22.4	
Hodgkin Lymphoma	4.1	3.1	3.2	3.5	3.1	568	3.4	
Non-Hodgkin Lymphoma	19.6	18.8	19.1	19.2	18.2	4,218	19.0	
Myelomas	4.9	4.6	5.2	4.6	4.8	1,102	4.8	
Leukemias	11.2	11.0	11.6	11.9	11.7	2,470	11.5	
Lymphocytic Leukemia	4.9	5.5	6.0	5.4	6.0	1,196	5.5	
Acute Lymphocytic Leukemia	1.4	1.5		1.6	1.7	246		
Chronic Lymphocytic Leukemia	3.1	3.8		3.5	3.9	889	3.7	
Myeloid and Monocytic Leukemia	5.6	4.9	5.1	5.6	5.2	1,129	5.3	
Acute Myeloid Leukemia	3.8	3.3	3.2	4.2	3.4	774	3.6	
Acute Monocytic Leukemia	0.3	0.2	0.3	0.2	0.3	47	0.2	
Chronic Myeloid Leukemia	1.3	1.1	1.6	1.1	1.4	273	1.3	
Other Leukemia	0.8	0.6	0.5	0.8	0.5	145	0.6	
Mesothelioma	1.0	0.5	0.6	0.6	0.5	150	0.7	
Kaposi Sarcoma	-	0.1	0.1	0.2	-	29	0.1	
Ill-Defined & Unspecified Sites*	15.9	15.1	15.2	14.0	14.7	3,631	15.0	

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 5. Age-adjusted Incidence Rates, Black Males

			Rates		Rates		
Cancer Site	2008	2009	2010	2011	2012 Prelim.	2008	-2012
All Sites*	612.8	643.5	586.3	547.8	520.7	13,753	580.1
Oral Cavity and Pharynx	12.5	12.7	12.6	10.2	13.4	320	12.3
Lip	12.3	12.7	12.0	10.2	13.4	320	12.3
Tongue	3.7	3.1	2.2	3.5	3.2	83	3.1
Salivary Gland	1.2	1.6		3.3	3.2	25	1.0
Floor of Mouth	1.2	0.9		_	-	16	0.6
Gum and Other Mouth	1.9	1.4		1.3	2.1	37	1.6
Nasopharynx	1.6	1.4		1.5	1.4	35	1.0
Tonsil	1.6	1.8		1.7	2.8	57	2.2
Oropharynx	0.9	1.0	1.3		0.8	26	0.9
Hypopharynx	1.2	1.5		1.4	1.9	33	1.4
	1.2	1.3	_	1.7	1.7	33	1,7
Digestive System	129.8	137.8	131.0	101.6	109.4	2,804	121.4
Esophagus	9.5	8.6		6.1	5.3	186	8.1
Stomach	16.1	15.4		9.5	13.4	288	13.4
Small Intestine	3.1	6.2	2.2		3.1	86	
Colon and Rectum	59.9	65.7			49.7	1,274	56.8
Colon excluding Rectum	45.1	45.6			36.2	892	41.0
Rectum and Rectosigmoid Junction	14.8	20.0		13.5	13.5	382	15.7
Anus, Anal Canal and Anorectum	2.3	2.0	3.0	2.0	1.5	61	2.2
Liver and Intrahepatic Bile Duct	17.2	14.3			12.6	412	14.9
Liver	16.2	14.2	16.6		12.4	398	14.4
Intrahepatic Bile Duct	_	-	1.1	-	_	14	0.6
Gallbladder	1.5	1.9	1.4	-	1.2	27	1.3
Other Biliary	1.4	2.9			1.7	36	1.9
Pancreas	17.7	19.7	18.1	13.2	18.7	398	17.4
Respiratory System	89.6	95.5	83.3	78.4	79.9	1,885	85.1
Larynx	8.7	8.5		5.9	4.6	173	7.1
Lung and Bronchus	79.9	86.2			74.0		
Bones and Joints	0.9	0.9	0.7	-	0.7	24	0.7
Soft Tissue (Including Heart)	2.8	4.6	3.6	2.9	3.7	101	3.5
Skin (Excluding Basal and Squamous)	2.0	1.7	2.0	2.1	2.2	54	2.0
Melanoma of the Skin	_	_	1.1		_	19	0.8

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.
*All ICD-O-3 invasive reportable cases are included.
- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 5 (continued). Age-adjusted Incidence Rates, Black Males

			Cases	Rates			
Cancer Site	2008	2009	2010	2011	2012 Prelim.	2008-	-2012
Breast	1.9	1.7	2.2	1.5	1.6	41	1.8
Male Genital System	240.6	249.5	231.1	231.3	184.3	5,516	226.3
Prostate	238.6	248.1	228.0	228.8	181.5	5,451	224.0
Testis	1.0	1.1	1.9	1.6	1.6	43	1.4
Penis	1.0	-	-	-	1.3	19	0.8
Urinary System	47.3	47.3	41.5	47.7	46.6	1,043	46.1
Urinary Bladder (Including in situ)	25.0	23.8	20.6	22.5	20.8	449	22.5
Kidney and Renal Pelvis	21.3	22.4	20.6	24.7	24.7	578	22.8
Ureter	-	-	-	-	-	5	0.3
Eye and Orbit	-	-	-	-	-	5	0.2
Brain and Other Nervous System	5.8	4.9	5.6	4.4	5.1	135	5.2
Brain	5.2	4.4	5.0	4.0	4.6	120	4.6
Endocrine System	5.6	5.4	4.0	4.9	6.0	139	5.2
Thyroid	4.5	4.1	3.2	4.1	4.9	110	4.1
Lymphomas	23.0	22.5	20.2	18.0	19.6	550	20.6
Hodgkin Lymphoma	4.2	3.6	3.7	2.0	3.5	105	3.4
Non-Hodgkin Lymphoma	18.8	18.9	16.5	16.0	16.1	445	17.2
Myelomas	14.3	15.1	13.3	13.4	14.0	317	14.0
Leukemias	12.6	13.1	12.7	11.7	14.2	305	12.9
Lymphocytic Leukemia	5.4	4.7	5.7	5.2	7.6	136	5.7
Acute Lymphocytic Leukemia	0.8	1.5	1.5	0.7	1.1	38	1.1
Chronic Lymphocytic Leukemia	3.9	2.9	4.1	3.6	6.5	88	4.2
Myeloid and Monocytic Leukemia	6.6	6.3	6.0	5.5	6.0	147	6.1
Acute Myeloid Leukemia	2.9	3.9	3.9	4.2	3.9	89	3.8
Acute Monocytic Leukemia	-	-	-	-	-	-	-
Chronic Myeloid Leukemia	2.7	2.1	1.8	1.2	1.8	49	1.9
Other Leukemia	-	2.0	-	0.9	-	22	1.0
Mesothelioma	-	2.4	1.4	-	-	25	1.3
Kaposi Sarcoma	1.2	1.7	1.1	1.5	1.2	41	1.4
Ill-Defined & Unspecified Sites*	22.0	26.6	19.9	16.6	17.5	448	20.4

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 6. Age-adjusted Incidence Rates, Black Females

			Rates		Cases Ra			
Cancer Site	2008	2009 2010		2011	2012 Prelim.	2008-2012		
All Sites*	408.7	407.2	412.1	385.5	391.9	13,498	400.8	
Oral Cavity and Pharynx	4.4	4.9	4.2	4.3	5.7	169	4.7	
Lip	-	-	-	-	-	-	-	
Tongue	1.3	0.7	1.2	-	2.1	42	1.2	
Salivary Gland	1.3	0.9	-	1.4	0.8	34	1.0	
Floor of Mouth	_	-	-	-	-	7	0.2	
Gum and Other Mouth	_	1.1	0.8	0.7	1.3	30		
Nasopharynx	_	-	0.8	-	-	14		
Tonsil	_	0.8	_	_	_	16		
Oropharynx	_	-	-	_	-	12	0.3	
Hypopharynx	-	-	-	-	-	11	0.3	
Digestive System	88.2	79.7	83.0	84.2	81.8	2,721	83.3	
Esophagus	3.5	2.2	2.3	2.6	3.5	94	2.8	
Stomach	8.7	8.8	9.2	8.7	7.3	274		
Small Intestine	3.5	2.9	3.0		2.6	88		
Colon and Rectum	46.1	40.0	44.4	44.1	43.1	1,424		
Colon excluding Rectum	34.5	28.6	34.7	33.8	32.9	1,072		
Rectum and Rectosigmoid Junction	11.6	11.4	9.8	10.3	10.2	352	10.7	
Anus, Anal Canal and Anorectum	1.5	1.8	1.5	2.2	1.8	60	1.8	
Liver and Intrahepatic Bile Duct	4.5	3.8	3.9	3.6	4.4	138		
Liver	3.2	3.7	3.3	3.4	3.9	120		
Intrahepatic Bile Duct	1.3	_	_	_	_	18		
Gallbladder	2.2	1.7	2.3	2.2	2.0	71	2.1	
Other Biliary	1.3	1.6	1.5	1.6	0.8	44	1.4	
Pancreas	14.9	15.0	13.5	15.6	14.7	471	14.7	
Respiratory System	56.2	50.7	53.6	47.0	45.5	1,647	50.5	
Larynx	2.1	1.9	1.3	0.8	1.5	52	1.5	
Lung and Bronchus	53.7	47.6	51.7		43.8	1,574		
Bones and Joints	_	0.9	0.7	-	-	18	0.5	
Soft Tissue (Including Heart)	3.2	3.4	2.9	4.0	2.8	112	3.2	
Skin (Excluding Basal and Squamous)	1.7	2.1	1.8	1.6	1.3	59	1.7	
Melanoma of the Skin	0.8	1.3	1.0		0.8	34		
Breast (Invasive)	121.2	123.9	119.7	114.0	118.4	4,138	119.4	
In situ (not included in All Sites)	29.7	29.0	32.2		33.7	1,123		

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 6 (continued). Age-adjusted Incidence Rates, Black Females

			Rates	Cases Rates			
Cancer Site	2008	2009 52.6	2010	2011 45.9	2012 Prelim. 50.4	2008-2012	
Female Genital System	50.9					1,750	51.0
Cervix Uteri	10.3	11.5	11.8	9.7	9.8	374	10.6
Corpus and Uterus, NOS	24.7	27.1	29.5	24.8	25.8	907	26.4
Corpus Uteri	23.2	24.7	27.4	22.0	23.8	833	24.2
Uterus, NOS	1.5	2.4	2.1	2.8	2.0	74	2.2
Ovary	11.8	10.0	10.4	9.0	11.1	346	10.4
Vagina	1.7	0.8	0.8	-	1.2	35	1.0
Vulva	1.5	2.0	1.9	1.1	2.1	60	1.7
Urinary System	19.0	19.6	20.5	18.6	20.3	636	19.6
Urinary Bladder (Including in situ)	7.6	7.8	9.0	7.2	7.4	240	7.8
Kidney and Renal Pelvis	10.7	11.5	10.8	11.0	11.9	376	11.2
Ureter	-	-	-	-	-	6	0.2
Eye and Orbit	-	-	-	-	-	6	0.2
Brain and Other Nervous System	2.5	4.5	4.2	3.0	2.6	117	3.3
Brain	1.8	4.0	3.6	2.7	2.2	100	2.9
Endocrine System	13.3	12.6	14.7	13.2	12.8	474	13.3
Thyroid	12.0	11.6	12.8	12.6	12.1	436	12.2
Lymphomas	13.6	16.8	12.7	15.1	12.6	482	14.2
Hodgkin Lymphoma	2.4	2.5	1.6	3.3	1.6	81	2.3
Non-Hodgkin Lymphoma	11.2	14.3	11.1	11.8	11.0	401	11.9
Myelomas	9.7	11.8	11.5	10.5	9.7	356	10.6
Leukemias	6.9	7.4	8.1	7.8	9.5	260	8.0
Lymphocytic Leukemia	1.8	3.1	4.4	3.8	3.1	105	3.3
Acute Lymphocytic Leukemia	1.0	-	-	1.0	-	25	0.7
Chronic Lymphocytic Leukemia	0.8	2.3	3.3	2.6	2.2	71	2.3
Myeloid and Monocytic Leukemia	4.6	3.5	3.4	3.5	5.7	138	4.1
Acute Myeloid Leukemia	3.6	1.4	1.9	2.0	3.3	81	2.4
Acute Monocytic Leukemia	-	-	-	-	-	-	-
Chronic Myeloid Leukemia	1.0	1.6	1.3	1.6	2.3	52	1.6
Other Leukemia	-	0.8	-	-	-	17	0.6
Mesothelioma	-	-	-	-	-	6	0.2
Kaposi Sarcoma	-	-	-	-	-	11	0.3
Ill-Defined & Unspecified Sites*	16.8	15.2	18.9	15.1	17.4	536	16.7

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 7. Age-adjusted Incidence Rates, Hispanic Males

			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012 Prelim.	2008	-2012
All Sites*	486.7	463.6	471.4	456.1	437.6	9,911	461.7
Oral Cavity and Pharynx	9.1	10.5	12.5	13.7	11.3	262	11.5
Lip	-	-	-	1.8	-	12	0.7
Tongue	2.9	3.5	3.8	3.6	3.5	78	3.5
Salivary Gland	2.5	-	-	0.9	1.4	25	1.2
Floor of Mouth	-	-	-	-	-	10	0.4
Gum and Other Mouth	-	-	-	2.0	2.3	27	1.1
Nasopharynx	-	1.1	1.7	1.6	-	24	1.1
Tonsil	0.9	2.3	2.4	1.6	1.6	48	1.7
Oropharynx	-	-	1.3	-	-	12	0.5
Hypopharynx	-	-	1.7	1.3	-	22	1.1
Digestive System	113.5	101.6	103.3	102.8	108.2	2,220	105.8
Esophagus	6.0	4.7	8.3	4.8	6.7	121	6.1
Stomach	21.3	17.1	15.4	13.5	15.1	317	16.3
Small Intestine	1.5	1.6	1.4	1.8	2.4	40	1.8
Colon and Rectum	52.2	46.9	44.6	42.9	47.4	987	46.6
Colon excluding Rectum	35.9	32.1	31.1	29.3	32.1	645	32.0
Rectum and Rectosigmoid Junction	16.3	14.8	13.5	13.6	15.3	342	14.6
Anus, Anal Canal and Anorectum	2.3	-	2.0	1.6	1.1	35	1.4
Liver and Intrahepatic Bile Duct	10.9	15.2	15.6	17.0	17.5	359	15.4
Liver	10.7	13.9	14.5	15.8	15.9	337	14.3
Intrahepatic Bile Duct	-	-	1.1	-	1.6	22	1.1
Gallbladder	_	-	-	2.8	_	23	1.4
Other Biliary	4.0	3.6	2.6	2.8	2.9	58	3.1
Pancreas	13.3	10.7	11.1	14.3	12.9	256	12.5
Respiratory System	58.2	50.4	54.5	51.2	54.2	1,003	53.6
Larynx	7.0	7.1	7.0	5.3	4.3	121	6.0
Lung and Bronchus	49.9	42.4		45.0		851	46.5
Bones and Joints	1.3	0.7	1.1	0.9	1.0	37	1.0
Soft Tissue (Including Heart)	2.5	4.9	4.3	3.2	3.0	103	3.6
Skin (Excluding Basal and Squamous)	6.9	5.8		5.3	6.0	135	5.8
Melanoma of the Skin	6.0	3.9		3.6	5.3	111	4.7

^{*}All ICD-O-3 invasive reportable cases are included.

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 7 (continued). Age-adjusted Incidence Rates, Hispanic Males

			Rates			Cases Rates	
Cancer Site	2008	2009	2010	2011	2012 Prelim.	2008-	-2012
Breast	-	-	-	-	-	14	0.7
Male Genital System	166.0	158.7	155.6	157.3	123.7	3,210	151.3
Prostate	158.5	153.5	149.7	151.0	118.3	2,979	145.2
Testis	4.4	4.4	4.7	4.9	3.9	196	4.5
Penis	3.2	-	-	1.2	1.4	30	1.4
Urinary System	41.9	44.2	52.0	40.1	43.4	875	44.3
Urinary Bladder (Including in situ)	24.2	26.6	27.3	23.5	27.8	437	25.9
Kidney and Renal Pelvis	16.4	16.8	22.7	15.4	14.4	418	17.1
Ureter	-	-	-	-	-	9	0.5
Eye and Orbit	-	-	-	-	-	10	0.4
Brain and Other Nervous System	8.6	7.0	6.2	6.1	8.7	228	7.3
Brain	8.0	6.4	5.8	5.7	8.2	212	6.9
Endocrine System	6.3	6.2	6.4	6.8	7.7	212	6.7
Thyroid	4.7	6.0	5.8	6.4	7.5	192	6.2
Lymphomas	28.8	25.2	27.1	26.6	26.0	678	26.7
Hodgkin Lymphoma	2.8	3.1	2.8	2.5	2.9	99	2.8
Non-Hodgkin Lymphoma	26.0	22.1	24.3	24.1	23.1	579	23.9
Myelomas	7.1	9.1	8.2	7.0	11.1	179	8.5
Leukemias	14.1	14.1	14.8	15.0	16.1	362	14.8
Lymphocytic Leukemia	4.6	5.9	6.8	7.8	7.6	170	6.7
Acute Lymphocytic Leukemia	1.3	2.8	2.0	2.1	2.5	87	2.2
Chronic Lymphocytic Leukemia	2.8	2.3	4.0	4.8	3.7	60	3.5
Myeloid and Monocytic Leukemia	8.1	6.5	7.3	6.8	8.0	169	7.3
Acute Myeloid Leukemia	3.9	2.5	4.9	3.9	4.3	94	3.9
Acute Monocytic Leukemia	-	-	-	-	-	5	0.2
Chronic Myeloid Leukemia	2.7	3.1	2.2	2.6	2.9	60	2.7
Other Leukemia	1.4	1.7	0.7	-	-	23	0.9
Mesothelioma	-	1.7	-	1.4	-	24	1.2
Kaposi Sarcoma	0.7	_	0.7	0.9	-	22	0.7
Ill-Defined & Unspecified Sites* Rates are per 100,000 population and age-adjusted to	18.7	22.1	16.9	16.5	15.3	337	17.8

^{*}All ICD-O-3 invasive reportable cases are included.

 $^{- \} Counts \ and \ rates \ are \ suppressed \ when \ fewer \ than \ 5 \ cases \ to \ ensure \ confidentiality \ and \ statistical \ reliability.$

Table 8. Age-adjusted Incidence Rates, Hispanic Females

			Rates			Cases Rates			
Cancer Site	2008	2009	2010	2011	2012	2008-	2012		
					Prelim.				
All Sites*	362.8	355.6	347.2	349.5	367.3	10,336	356.4		
0.10.11.10									
Oral Cavity and Pharynx	5.2	5.9	3.2	5.3	4.9	140	4.9		
Lip	-	-	-	-	-	5	0.2		
Tongue	1.1	1.3	1.1	1.9	-	33	1.2		
Salivary Gland	1.6	-	0.9	0.6	0.8	27	0.9		
Floor of Mouth	-	-	-	-	-	5	0.2		
Gum and Other Mouth	1.6	1.5	-	1.1	2.0	38	1.4		
Nasopharynx	-	-	-	-	-	11	0.3		
Tonsil	-	1.0	-	-	-	12	0.4		
Oropharynx	-	-	-	-	-	-	-		
Hypopharynx	-	-	-	-	-	-	-		
Digestive System	60.0	71.5	70.6	75.0	74.0	1.050	72.0		
Esophagus	68.0	71.5	70.6	75.2	74.0	1,859	72.0		
Stomach	2.7	1.1	10.7	1.7	- 11.0	32	1.3		
Small Intestine	9.2	8.5	10.7	8.1	11.8	257	9.7		
	2.6	1.4	1.5	2.0	-	43	1.6		
Colon and Rectum	32.4	35.0	36.0	35.5	35.2	908	34.9		
Colon excluding Rectum	23.4	24.6	26.5	25.5	25.3	639	25.1		
Rectum and Rectosigmoid Junction	9.0	10.4	9.6	9.9	10.0	269	9.8		
Anus, Anal Canal and Anorectum	2.2	2.5	2.9	2.8	2.6	71	2.6		
Liver and Intrahepatic Bile Duct	4.5	5.1	5.1	3.8	6.1	127	4.9		
Liver	4.1	3.5	3.8	2.5	5.4	102	3.9		
Intrahepatic Bile Duct	-	1.6	1.3	1.3	-	25	1.1		
Gallbladder	1.3	2.5	2.4	2.4	2.5	57	2.2		
Other Biliary	1.4	2.6	1.3	2.8	1.9	48	2.0		
Pancreas	9.7	11.3	9.6	14.2	11.1	276	11.3		
Respiratory System	20.0	21.6	25.6	20.0	20.0	764	20.7		
Larynx	30.8	31.6	25.6	30.9	29.9	764	29.7		
¥	-	- 21.0	1.5	1.0	1.3	24	0.9		
Lung and Bronchus	29.8	31.0	23.2	28.8	28.3	720	28.1		
Bones and Joints	1.0	1.2	1.2	1.0	1.1	42	1.1		
Soft Tissue (Including Heart)	3.1	2.5	1.8	1.1	2.7	70	2.2		
~ ~									
Skin (Excluding Basal and Squamous)	5.9	4.5	4.7	3.6	5.2	143	4.8		
Melanoma of the Skin	4.6	3.9	4.4	3.0	4.2	122	4.0		
Breast (Invasive)	95.9	98.3	90.7	92.2	97.1	2,902	94.8		
In situ (not included in All Sites)	28.2	26.2	31.0	25.0	26.6	876	27.4		

^{*}All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 8 (continued). Age-adjusted Incidence Rates, Hispanic Females

			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008	-2012
					Prelim.		
Female Genital System	52.0	45.3	52.2	47.8	51.1	1,501	49.7
Cervix Uteri	12.4	9.6	9.6	11.3	10.7	360	10.7
Corpus and Uterus, NOS	24.0	23.3	27.0	23.1	24.5	719	24.3
Corpus Uteri	23.3	21.9	26.4	21.7	23.6	691	23.4
Uterus, NOS	-	1.3	-	1.3	0.9	28	1.0
Ovary	12.5	9.2	10.7	9.8	10.3	314	10.5
Vagina	-	-	-	-	1.4	20	0.8
Vulva	1.8	1.6	3.0	2.3	2.9	60	2.4
Urinary System	19.4	18.1	15.4	13.6	19.2	456	17.1
Urinary Bladder (Including in situ)	8.7	6.6	8.5	4.6	7.0	169	7.0
Kidney and Renal Pelvis	10.2	11.4	6.7	8.8	11.5	278	9.7
Ureter	-	-	-	-	-	-	-
Eye and Orbit	_	_	_	-	_	13	0.4
·						10	J
Brain and Other Nervous System	4.1	5.2	4.3	4.7	5.7	159	4.8
Brain	4.1	4.5	3.9	4.3	5.0	143	4.4
Endocrine System	25.1	22.4	25.6	22.7	20.2	202	25.2
Thyroid	25.1	23.4	25.6	23.7	28.3	892	25.3
Thyroid	24.7	23.2	25.1	22.9	27.3	871	24.7
Lymphomas	20.1	21.3	21.6	18.3	17.1	575	19.6
Hodgkin Lymphoma	3.1	2.3	2.8	3.2	2.8	106	2.8
Non-Hodgkin Lymphoma	17.0	19.1	18.8	15.1	14.2	469	16.7
Myelomas	5.2	5.9	6.4	6.6	7.0	165	6.2
Leukemias	10.5	9.8	9.9	12.2	9.9	315	10.5
Lymphocytic Leukemia	4.3	4.2	4.8	5.2	4.5	141	4.6
Acute Lymphocytic Leukemia	2.4	1.8			2.4	80	
Chronic Lymphocytic Leukemia	1.3	2.2	3.2	2.9	2.0	56	
Myeloid and Monocytic Leukemia	5.4	5.5	4.3	6.0	4.6	152	5.1
Acute Myeloid Leukemia	4.1	4.1	3.2	3.3	3.2	103	3.5
Acute Monocytic Leukemia	-	-	-	-	-	6	0.2
Chronic Myeloid Leukemia	1.1	1.1	1.1	1.7	1.1	38	1.2
Other Leukemia	-	-	0.8	1.1	0.8	22	0.7
Mesothelioma	_	-	-	-	-	11	0.4
Kaposi Sarcoma	-	-	-	-	-	5	0.2
Ill-Defined & Unspecified Sites*	15.6	10.2	13.6	11.7	13.3	324	12.8
Pates are per 100 000 population and age adjusted t							

^{*}All ICD-O-3 invasive reportable cases are included.
- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 9. Age-adjusted Incidence Rates, Asian and Pacific Islander Males and Females, 2008-2012 Combined

	Ma	ale	Fen	nale
Cancer Site	Rate	Cases	Rate	Cases
All Sites*	286.7	3,960	267.6	4,719
Oral Cavity and Pharynx	11.8	182	3.4	63
Lip	-	-	-	-
Tongue	2.8	44	1.1	19
Salivary Gland	1.2	16	0.5	11
Floor of Mouth	0.5	6	-	-
Gum and Other Mouth	3.4	52	0.8	13
Nasopharynx	2.1	38	0.6	13
Tonsil	0.4	7	-	-
Oropharynx	0.4	6	-	-
Hypopharynx	0.9	11	-	-
Digestive System	77.6	1,036	50.8	786
Esophagus	3.9	50	1.4	18
Stomach	12.2	156	7.3	109
Small Intestine	0.7	130	0.7	13
Colon and Rectum	32.9	443	24.4	385
Colon excluding Rectum	21.8	271	15.9	242
Rectum and Rectosigmoid Junction	11.1	172	8.5	143
Anus, Anal Canal and Anorectum	11.1	172	0.5	8
Liver and Intrahepatic Bile Duct	13.5	195	5.2	80
Liver and intranspatie Bite Bact	12.2	180	4.4	68
Intrahepatic Bile Duct	1.3	150	0.7	12
Gallbladder	0.9	15	1.9	29
Other Biliary	2.9	38	1.6	23
Pancreas	9.8	116		104
rancicas	9.8	110	6.9	104
Respiratory System	38.6	478	24.1	359
Larynx	2.7	38	0.4	7
Lung and Bronchus	35.2	428	23.3	345
Bones and Joints	0.4	9	0.6	11
Dones and Comes	0.4		0.0	11
Soft Tissue (Including Heart)	1.5	27	2.0	39
Skin (Excluding Basal and Squamous)	2.4	32	1.5	26
Melanoma of the Skin	1.8	21	0.9	
Breast (Invasive)	1.0	12	88.0	1,687
In situ (not included in All Sites)	1.0	12	31.8	636
Rates are per 100 000 population and age-adjusted to the 200	0.77.0	<u> </u>	51.0	030

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard. *All ICD-O-3 invasive cases are included.

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 9 (continued). Age-adjusted Incidence Rates, Asian and Pacific Islander
Males and Females, 2008-2012 Combined

	ales and Female				
	Ma		Fen		
Cancer Site	Rate	Cases	Rate	Cases	
Female Genital System	^	^	33.1	615	
Cervix Uteri	٨	۸	4.8	95	
Corpus and Uterus, NOS	^	^	16.1	308	
Corpus Uteri	^	^	15.1	294	
Uterus, NOS	٨	۸	1.0	14	
Ovary	^	^	9.8	175	
Vagina	^	۸	0.7	11	
Vulva	^	^	1.2	15	
Male Genital System	73.9	1,045	۸	^	
Prostate	71.3	1,002	۸	^	
Testis	1.7	35	^	^	
Penis	0.7	7	۸	^	
Urinary System	23.1	302	8.1	128	
Urinary Bladder (Including in situ)	13.3	154	3.2	48	
Kidney and Renal Pelvis	8.9	138	4.5	75	
Ureter	0.5	6	-	-	
Eye and Orbit	0.3	7	-	-	
Brain and Other Nervous System	4.7	85	3.2	57	
Brain	4.4	80	3.0	51	
Endocrine System	8.3	153	23.5	484	
Thyroid	7.3	135	22.8	471	
Lymphomas	16.1	235	11.9	197	
Hodgkin Lymphoma	1.8	33	1.2	24	
Non-Hodgkin Lymphoma	14.3	202	10.7	173	
Myelomas	4.5	60	3.1	53	
Leukemias	9.1	140	6.1	103	
Lymphocytic Leukemia	4.7	70	1.8	33	
Acute Lymphocytic Leukemia	2.2	36	1.2	25	
Chronic Lymphocytic Leukemia	2.3	30	0.5	7	
Myeloid and Monocytic Leukemia	4.1	64	3.8	63	
Acute Myeloid Leukemia	2.1	33	3.0	47	
Acute Monocytic Leukemia	-	-	-	-	
Chronic Myeloid Leukemia Other Leukemia	1.7 0.3	27 6	0.7 0.5	13 7	
Mesothelioma Kaposi Sarcoma	-	-	-	-	
Napusi Sai Cuilia	_	-	-	-	
Ill-Defined & Unspecified Sites*	12.8	149	8.0	109	

^{*}All ICD-O-3 invasive cases are included.

[^] Non-applicable gender.

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 10. Benign and Borderline Brain Tumor Incidence Rates, New Jersey, 2008-2012

				Rates			Cases	Rates
	Site Group	2008	2009	2010	2011	2012	2008	-2012
Population						Prelim.		
Total	Brain	1.2	1.1	1.1	1.3	1.3	552	1.2
	Intracranial Meninges	6.5	6.6	6.5	6.4	7.1	3,254	6.6
	Cranial Nerves and other CNS	1.5	1.7	1.6	1.7	1.8	793	1.6
	Tumors of the Sellar Region	3.3	3.6	3.5	3.3	3.5	1,564	3.4
	Spinal Cord	0.6	0.5	0.7	0.5	0.5	258	0.6
	Spinal Meninges	0.5	0.6	0.3	0.3	0.3	186	0.4
	Total	13.5	14.1	13.6	13.4	14.4	6,607	13.8
Male	Brain	1.6	1.2	1.1	1.3	1.5	290	1.3
	Intracranial Meninges	4.6	4.6	4.7	4.0	4.8	957	4.5
	Cranial Nerves and other CNS	1.5	1.7	1.6	1.7	1.7	374	1.6
	Tumors of the Sellar Region	3.0	3.5	2.8	3.3	3.2	702	3.2
	Spinal Cord	0.5	0.5	0.8	0.5	0.4	122	0.6
	Spinal Meninges	0.2	0.3	0.1	0.1	0.2	43	0.2
	Total	11.5	11.7	11.1	10.9	11.8	2,488	11.4
Female	Brain	0.9	1.1	1.1	1.3	1.2	262	1.1
	Intracranial Meninges	8.1	8.4	8.1	8.5	9.0	2,297	8.4
	Cranial Nerves and other CNS	1.5	1.6	1.6	1.7	1.8	419	1.6
	Tumors of the Sellar Region	3.6	3.7	4.1	3.3	3.8	862	3.7
	Spinal Cord	0.6	0.5	0.6	0.5	0.6	136	0.6
	Spinal Meninges	0.7	0.8	0.4	0.4	0.3	143	0.5
	Total	15.4	16.1	15.9	15.7	16.7	4,119	16.0
White	Brain	1.3	1.1	1.1	1.3	1.4	433	1.2
	Intracranial Meninges	6.3	6.5	6.3	6.2	6.9	2,593	6.4
	Cranial Nerves and other CNS	1.7	1.8	1.7	1.8	1.9	664	1.8
	Tumors of the Sellar Region	2.8	3.4	3.4	3.1	3.2	1,112	3.2
	Spinal Cord	0.7	0.5	0.7	0.5	0.5	207	0.6
	Spinal Meninges	0.5	0.6	0.3	0.3	0.3	160	0.4
	Total	13.2	14.0	13.5	13.1	14.2	5,169	13.6
Black	Brain	1.4	1.2	0.8	1.0	1.1	66	1.1
	Intracranial Meninges	7.2	7.8	8.1	7.7	8.3	447	7.8
	Cranial Nerves and other CNS	0.6	0.7	-	0.8	0.7	40	0.6
	Tumors of the Sellar Region	5.9	5.5	4.6	4.5	4.8	318	5.0
	Spinal Cord	-	0.5	0.4	0.4	-	25	0.4
	Spinal Meninges	15.7	15.0	- 1.4.4	- 147	1.5.0	10	0.2
	Total	15.7	15.9	14.4	14.7	15.2	906	15.2

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 11. Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders Incidence Rates, New Jersey, 2008-2012

				Rates			Cases	Rates
Pop	oulation	2008	2009	2010	2011	2012	2008-2	2012
						Prelim.		
	Γotal	9.1	8.5	8.6	7.8	7.3	4,035	8.2
]	Male	11.9	11.0	11.3	10.2	10.1	2,201	10.9
F	emale	7.2	6.7	6.7	6.1	5.5	1,834	6.5
Myelodysp	lastic Syndrome	s (MDS)						
Male	All races	7.7	7.9	8.3	7.4	7.7	1,538	7.8
Male	White	8.1	8.0	8.7	8.0	8.2	1,374	8.2
Male	Black	4.6	7.9	4.7	2.2	5.6	96	5
Male	API	5.4	5.4	3.2	5.6	3.5	44	4.6
Male	Hispanic*	7.4	10.0	5.2	7.3	3.5	113	6.6
Female	All races	4.5	3.8	4.2	4.4	3.7	1,183	4.1
Female	White	4.6	3.8	4.2	4.4	3.5	997	4.1
Female	Black	4.2	3.9	4.2	3.5	4.5	131	4.1
Female	API	2.5	-	3.3	3.1	2.6	35	2.7
Female	Hispanic**	3.4	3.9	4.2	2.6	3.2	81	3.4
Chronic M	yeloproliferative	Disorders ((CMD)					
Male	All races	4.1	3.1	3.0	2.8	2.3	663	3.1
Male	White	4.1	3.0	2.9	2.7	2.4	534	3.0
Male	Black	4.5	3.7	3.8	2.5	2.1	84	3.3
Male	API	2.3	-	1.8	1.8	1.5	28	1.6
Male	Hispanic**	3.9	4.6	2.4	2.9	2.3	70	3.2
Female	All races	2.7	2.9	2.6	1.8	1.9	651	2.4
Female	White	2.8	2.9	2.3	1.7	2.0	533	2.4
Female	Black	2.7	2.8	4.1	1.8	1.6	85	2.6
Female	API	-	1.7	-	2.2	-	23	1.5
Female	Hispanic**	3.6	1.8	2.7	1.1	1.4	56	2.0

Rates are per 100,000 and age-adjusted to the 2000 US standard population. MDS includes ICD-O-3 histology codes 9980, 9982, 9983, 9984, 9985, 9986, 9987, 9989.

CMD includes ICD-O-3 histology codes 9950, 9960, 9961, 9962, 9963, 9964.

^{*}Hispanic includes all races.

⁻ Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 12. Distribution of Stage at Diagnosis for Selected Cancer Sites in New Jersey, Males, 2008-2012

Wrates, 2008-2012										
	All									
	Races	White	Black	API	Hispanic*					
Colorectal				1	T					
Total Cases	11,670	9,613	1,411	476	1,048					
Percent	100%	100%	100%	100%	100%					
In Situ	6.7%	6.0%	9.7%	6.9%	5.8%					
Local	34.2%	35.1%	28.4%	33.6%	34.4%					
Regional	32.1%	32.9%	28.8%	31.3%	34.0%					
Distant	19.2%	18.8%	23.7%	18.1%	17.8%					
Unstaged	8.0%	7.2%	9.4%	10.1%	8.0%					
Lung**										
Total Cases	14,600	12,431	1,678	428	851					
Percent	100%	100%	100%	100%	100%					
Local	17.1%	17.5%	14.2%	16.6%	16.6%					
Regional	22.7%	23.0%	21.5%	19.6%	21.9%					
Distant	51.5%	51.1%	53.9%	55.6%	53.6%					
Unstaged	8.8%	8.5%	10.4%	8.2%	8.0%					
Melanoma										
Total Cases	11,116	10,478	30	38	172					
Percent	100%	100%	100%	100%	100%					
In situ	45.6%	44.5%	36.7%	44.7%	35.5%					
Local	43.4%	44.3%	33.3%	29.0%	44.2%					
Regional	4.8%	5.0%	ı	18.4%	9.3%					
Distant	2.6%	2.7%	I	i	5.2%					
Unstaged	3.5%	3.6%	ı	-	5.8%					
Prostate**										
Total Cases	35,641	28,076	5,451	1,002	2,979					
Percent	100%	100%	100%	100%	100%					
Local	82.7%	83.0%	81.9%	80.7%	84.0%					
Regional	8.4%	8.8%	7.0%	11.2%	7.2%					
Distant	3.5%	3.3%	5.0%	4.6%	4.2%					
Unstaged	5.4%	4.9%	6.1%	3.5%	4.6%					

^{*}Hispanic includes all races.

Data are suppressed for fewer than 5 cases to ensure confidentiality and statistical reliability.

^{**}In situ cases not presented due to small numbers.

Table 13. Distribution of Stage at Diagnosis for Selected Cancer Sites in New Jersey, Females, 2008-2012

Breast White Black API Hispanic* Total Cases 45,566 37,526 5,261 2,323 3,778 Percent 100% 100% 100% 100% 100% In Situ 23.7% 23.6% 21.4% 27.4% 23.2% Local 47.1% 48.5% 40.7% 42.9% 43.1% Regional 21.5% 20.5% 28.0% 22.7% 25.9% Distant 4.8% 4.7% 6.5% 3.7% 4.9% Unstaged 2.9% 2.7% 3.5% 3.3% 2.9% Cervical** Total Cases 1,957 1,460 374 95 360 Percent 100% 100% 100% 100% 100% 100% Local 42.6% 44.3% 34.5% 47.4% 50.6% Regional 36.8% 35.3% 43.9% 37.9% 32.5% Distant 11.830 9.738 1,555 407	Females, 2000-2012										
Breast Total Cases 45,566 37,526 5,261 2,323 3,778 Percent 100% 100% 100% 100% 100% In Situ 23,7% 23,6% 21,4% 27,4% 23,2% Local 47,1% 48,5% 40,7% 42,9% 43,1% Regional 21,5% 20,5% 28,0% 22,7% 25,9% Distant 4,8% 4,7% 6,5% 3,7% 4,9% Unstaged 2,9% 2,7% 3,5% 3,3% 2,9% Unstaged 4,9% 44,3% 34,5% 47,4% 50,6% Regional 36,8% 35,3% 43,9% 37,9% 32,5% Distant 11,830 9,738 1,555 407		All Races	White	Black	API	Hispanic*					
Percent	Breast										
Percent 100% 100% 100% 100% In Situ 23.7% 23.6% 21.4% 27.4% 23.2% Local 47.1% 48.5% 40.7% 42.9% 43.1% Regional 21.5% 20.5% 28.0% 22.7% 25.9% Distant 4.8% 4.7% 6.5% 3.7% 4.9% Unstaged 2.9% 2.7% 3.5% 3.3% 2.9% Cervical** 7 1,460 374 95 360 Percent 100% 100% 100% 100% 100% Local 42.6% 44.3% 34.5% 47.4% 50.6% Regional 36.8% 35.3% 43.9% 37.9% 32.5% Distant 11.8% 11.6% 14.2% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 6.7% Colorectal 11.830 9,738 1,555 407 973 Percent	Total Cases	45,566	37,526	5,261	2,323	3,778					
Description Colorectal Co	Percent										
Local	In Situ				27.4%						
Regional 21.5% 20.5% 28.0% 22.7% 25.9% Distant 4.8% 4.7% 6.5% 3.7% 4.9% Unstaged 2.9% 2.7% 3.5% 3.3% 2.9% Cervical** Total Cases 1,957 1,460 374 95 360 Percent 100% 100% 100% 100% 100% 100% Local 42.6% 44.3% 34.5% 47.4% 50.6% 8egional 36.8% 35.3% 43.9% 37.9% 32.5% Distant 11.8% 11.6% 14.2% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 10.3% Unstaged 11,830 9,738 1,555 407 973 Percent 100% 100% 100% 100% 100% In Situ 5.8% 5.3% 8.4% 5.4%	Local	47.1%			42.9%						
Distant 4.8% 4.7% 6.5% 3.7% 4.9% Unstaged 2.9% 2.7% 3.5% 3.3% 2.9% Cervical** Total Cases Percent 100% 100% 100% 100% 100% Local 42.6% 44.3% 34.5% 47.4% 50.6% Regional 36.8% 35.3% 43.9% 37.9% 32.5% Distant 11.8% 11.6% 14.2% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 6.7% Colorectal Total Cases 11,830 9,738 1,555 407 973 Percent 100% 100% 100% 100% 100% 100% In Situ 5.8% 5.3% 8.4% 5.4% 6.7% Local 34.7% 35.1% 33.4% 31.7% 34.3% Regional 32.4% 33.2% 28.0% 33.9% 32.2%<	Regional	21.5%	20.5%	28.0%	22.7%	25.9%					
Cervical** Total Cases 1,957 1,460 374 95 360 Percent 100% 100% 100% 100% 100% 100% Local 42.6% 44.3% 34.5% 47.4% 50.6% Regional 36.8% 35.3% 43.9% 37.9% 32.5% Distant 11.8% 11.6% 14.2% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 6.7% Colorectal Total Cases 11,830 9,738 1,555 407 973 Percent 100% 100% 100% 100% 100% 100% In Situ 5.8% 5.3% 8.4% 5.4% 6.7% Local 34.7% 35.1% 33.4% 31.7% 34.3% Regional 32.4% 33.2% 28.0% 33.9% 32.2% Distant 17.9% 17.5% 20.4% 21.4% 17.1%	Distant	4.8%	4.7%	6.5%	3.7%						
Total Cases 1,957 1,460 374 95 360 Percent 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 36.6% 35.3% 43.9% 37.9% 32.5% Distant 11.8% 11.6% 14.2% 7.4% 10.3% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 10.3% 0.7% Colorectal Total Cases 11.830 9.738 1.555 407 973 973 Percent 100% 110% 110% 110% 110% 110% 110% 110% 110% 110	Unstaged	2.9%	2.7%	3.5%	3.3%	2.9%					
Percent 100% 100% 100% 100% Local 42.6% 44.3% 34.5% 47.4% 50.6% Regional 36.8% 35.3% 43.9% 37.9% 32.5% Distant 11.8% 11.6% 14.2% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 10.3% Colorectal 1 1.6% 1.42% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 6.7% Colorectal 1 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.00% 1.0.10% 1.0.10% 1.10% 1.10% 1.10% 1.0.10% 1.0.10% 1.00% 1.00% 1.00% </td <td>Cervical**</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Cervical**										
Percent 100% 100% 100% 100% Local 42.6% 44.3% 34.5% 47.4% 50.6% Regional 36.8% 35.3% 43.9% 37.9% 32.5% Distant 11.8% 11.6% 14.2% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 6.7% Colorectal Total Cases 11,830 9,738 1,555 407 973 Percent 100% 100% 100% 100% 100% In Situ 5.8% 5.3% 8.4% 5.4% 6.7% Local 34.7% 35.1% 33.4% 31.7% 34.3% Regional 32.4% 33.2% 28.0% 33.9% 32.2% Distant 17.9% 17.5% 20.4% 21.4% 17.1% Unstaged 9.2% 8.9% 9.8% 7.6% 9.8% Local 21.2% 21.7% 17.6% <td< td=""><td>Total Cases</td><td>1,957</td><td>1,460</td><td>374</td><td>95</td><td>360</td></td<>	Total Cases	1,957	1,460	374	95	360					
Regional 36.8% 35.3% 43.9% 37.9% 32.5% Distant 11.8% 11.6% 14.2% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 6.7% Colorectal Total Cases 11,830 9,738 1,555 407 973 Percent 100% 100% 100% 100% 100% In Situ 5.8% 5.3% 8.4% 5.4% 6.7% Local 34.7% 35.1% 33.4% 31.7% 34.3% Regional 32.4% 33.2% 28.0% 33.9% 32.2% Distant 17.9% 17.5% 20.4% 21.4% 17.1% Unstaged 9.2% 8.9% 9.8% 7.6% 9.8% Lung*** Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% 20.6% 21.3% Region	Percent	100%	100%	100%	100%	100%					
Distant 11.8% 11.6% 14.2% 7.4% 10.3% Unstaged 8.8% 8.9% 7.5% 7.4% 6.7% Colorectal Total Cases 11,830 9,738 1,555 407 973 Percent 100% 100% 100% 100% 100% 100% In Situ 5.8% 5.3% 8.4% 5.4% 6.7% Local 34.7% 35.1% 33.4% 31.7% 34.3% Regional 32.4% 33.2% 28.0% 33.9% 32.2% Distant 17.9% 17.5% 20.4% 21.4% 17.1% Unstaged 9.2% 8.9% 9.8% 7.6% 9.8% Lung** Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Unstaged	Local	42.6%	44.3%	34.5%	47.4%	50.6%					
National Colorectal National Colorectal	Regional	36.8%	35.3%	43.9%	37.9%	32.5%					
Colorectal Total Cases 11,830 9,738 1,555 407 973 Percent 100% 100% 100% 100% 100% 100% In Situ 5.8% 5.3% 8.4% 5.4% 6.7% Local 34.7% 35.1% 33.4% 31.7% 34.3% Regional 32.4% 33.2% 28.0% 33.9% 32.2% Distant 17.9% 17.5% 20.4% 21.4% 17.1% Unstaged 9.2% 8.9% 9.8% 7.6% 9.8% Lung*** Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases </td <td>Distant</td> <td>11.8%</td> <td>11.6%</td> <td>14.2%</td> <td>7.4%</td> <td>10.3%</td>	Distant	11.8%	11.6%	14.2%	7.4%	10.3%					
Total Cases 11,830 9,738 1,555 407 973 Percent 100% 100% 100% 100% 100% In Situ 5.8% 5.3% 8.4% 5.4% 6.7% Local 34.7% 35.1% 33.4% 31.7% 34.3% Regional 32.4% 33.2% 28.0% 33.9% 32.2% Distant 17.9% 17.5% 20.4% 21.4% 17.1% Unstaged 9.2% 8.9% 9.8% 7.6% 9.8% Lung*** Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221	Unstaged	8.8%	8.9%	7.5%	7.4%	6.7%					
Percent 100% 100% 100% 100% 100% In Situ 5.8% 5.3% 8.4% 5.4% 6.7% Local 34.7% 35.1% 33.4% 31.7% 34.3% Regional 32.4% 33.2% 28.0% 33.9% 32.2% Distant 17.9% 17.5% 20.4% 21.4% 17.1% Unstaged 9.2% 8.9% 9.8% 7.6% 9.8% Lung** Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835	Colorectal										
In Situ 5.8% 5.3% 8.4% 5.4% 6.7% Local 34.7% 35.1% 33.4% 31.7% 34.3% Regional 32.4% 33.2% 28.0% 33.9% 32.2% Distant 17.9% 17.5% 20.4% 21.4% 17.1% Unstaged 9.2% 8.9% 9.8% 7.6% 9.8% Lung** Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100%	Total Cases	11,830	9,738	1,555	407	973					
Local 34.7% 35.1% 33.4% 31.7% 34.3% Regional 32.4% 33.2% 28.0% 33.9% 32.2% Distant 17.9% 17.5% 20.4% 21.4% 17.1% Unstaged 9.2% 8.9% 9.8% 7.6% 9.8% Lung** Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% 100% In situ 50.2%	Percent	100%	100%	100%	100%	100%					
Regional 32.4% 33.2% 28.0% 33.9% 32.2% Distant 17.9% 17.5% 20.4% 21.4% 17.1% Unstaged 9.2% 8.9% 9.8% 7.6% 9.8% Lung** Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1%	In Situ	5.8%	5.3%	8.4%	5.4%	6.7%					
Distant 17.9% 17.5% 20.4% 21.4% 17.1% Unstaged 9.2% 8.9% 9.8% 7.6% 9.8% Lung** Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% <	Local	34.7%	35.1%	33.4%	31.7%	34.3%					
Unstaged 9.2% 8.9% 9.8% 7.6% 9.8% Lung** Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5%	Regional	32.4%	33.2%	28.0%	33.9%	32.2%					
Lung** Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%	Distant	17.9%	17.5%	20.4%	21.4%	17.1%					
Total cases 14,901 12,950 1,574 345 720 Percent 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%	Unstaged	9.2%	8.9%	9.8%	7.6%	9.8%					
Percent 100% 100% 100% 100% 100% Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%	Lung**										
Local 21.2% 21.7% 17.6% 20.6% 21.3% Regional 22.9% 23.2% 22.0% 16.2% 23.3% Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%	Total cases	14,901	12,950	1,574	345	720					
Regional 22.9% 23.2% 22.0% 16.2% 23.3% Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%	Percent	100%	100%	100%	100%	100%					
Distant 46.5% 45.8% 50.8% 52.8% 47.2% Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%	Local	21.2%	21.7%	17.6%	20.6%	21.3%					
Unstaged 9.3% 9.3% 9.6% 10.4% 8.2% Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%		22.9%	23.2%	22.0%	16.2%	23.3%					
Melanoma Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%		46.5%	45.8%	50.8%	52.8%	47.2%					
Total Cases 8,835 8,221 37 21 194 Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%	Unstaged	9.3%	9.3%	9.6%	10.4%	8.2%					
Percent 100% 100% 100% 100% 100% In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%	Melanoma										
In situ 50.2% 48.8% - 28.6% 37.1% Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%	Total Cases	8,835	8,221	37	21	194					
Local 41.1% 42.4% 48.7% 38.1% 46.9% Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%	Percent	100%	100%	100%	100%	100%					
Regional 3.4% 3.6% 13.5% - 4.6% Distant 1.8% 1.8% 13.5% - 4.6%	In situ	50.2%	48.8%		28.6%	37.1%					
Distant 1.8% 1.8% 13.5% - 4.6%	Local	41.1%	42.4%	48.7%	38.1%	46.9%					
110/0 110/0 1010/0	Regional	3.4%	3.6%	13.5%	-	4.6%					
Unstaged 3.6% 3.5% 16.2% - 6.7%	Distant	1.8%	1.8%	13.5%	-	4.6%					
5.070 5.270 - 0.770	Unstaged	3.6%	3.5%	16.2%	-	6.7%					

^{*}Hispanic includes all races.

Data are suppressed for fewer than 5 cases to ensure confidentiality and statistical reliability.
 **In situ cases not presented due to small numbers. In situ cervical cancers are not reportable.

Table 14. Comparative Incidence Rates, New Jersey and U.S., Males, 2008-2012

Cancer Site		New .	Jersey 20	008-2012	2	U.S. 2008-2012				
Population	All Races	White	Black	API*	Hispanic*	All Races	White	Black	API*	Hispanic*
All Sites	564.7	573.9	579.8	284.6	461.1	522.6	516.6	581.0	316.8	408.5
Prostate	157.3	150.3	223.3	70.6	145.0	131.5	121.4	205.1	67.8	112.1
Lung	69.3	70.6	76.9	34.8	46.8	76.7	76.2	91.2	47.4	43.3
Colorectal	50.9	51.0	56.9	32.9	46.5	48.3	47.1	59.1	39.1	44.6
Bladder**	42.1	45.8	22.5	13.2	25.8	36.4	38.6	19.5	15.4	20.1
Melanoma	27.9	32.6	0.8	1.8	4.6	25.4	28.4	1.1	1.5	4.7
Non-Hodgkin Lymphoma	25.4	26.8	17.2	14.2	23.8	23.1	23.7	17.0	15.7	19.9
Thyroid	9.4	10.3	4.1	7.3	6.2	6.8	7.3	3.6	6.3	5.1

^{*}API=Asians and Pacific Islanders; Hispanic includes all races.

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard).

Table 15. Comparative Incidence Rates, New Jersey and U.S., Females, 2008-2012

Cancer Site		New .	Jersey 20	008-2012	2	U.S. 2008-2012					
Population	All Races	White	Black	API*	Hispanic*	All Races	White	Black	API*	Hispanic*	
All Sites	450.5	468.9	401.0	266.6	355.9	419.0	424.9	400.6	287.5	330.4	
Breast (invasive)	130.2	134.5	119.4	87.8	94.9	123.1	124.2	121.8	88.3	91.9	
Lung	53.7	56.7	48.4	23.3	27.9	54.1	55.7	50.3	28.3	26.0	
Colorectal	39.4	39.2	43.5	24.3	34.8	36.6	35.7	43.4	29.2	30.6	
Endometrial (corpus uteri)	29.2	31.0	24.2	15.1	23.5	24.5	25.0	22.7	17.1	20.2	
Thyroid	27.0	29.7	12.2	22.7	24.6	20.3	21.3	12.7	20.4	19.3	
Non-Hodgkin Lymphoma	17.9	19.0	11.9	10.5	16.6	16.0	16.5	11.8	10.8	15.2	
Melanoma	16.9	20.5	1.0	0.9	4.0	15.9	18.3	1.0	1.2	4.0	
Bladder**	11.3	12.2	7.7	3.2	7.0	9.0	9.5	6.6	3.8	5.1	

^{*}API=Asians and Pacific Islanders; Hispanic includes all races.

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard).

^{**}Includes in situ cancers.

^{**}Includes in situ cancers.

Mortality Tables

Table 16. Age-adjusted Mortality Rates, Males, All Races Combined

G G'			Rates			2008-	2012
Cancer Site	2008	2009	2010	2011	2012	Cases	Rates
All Sites	206.2	199.3	202.8	195.7	191.7	41,147	199.0
Oral Cavity and Pharynx	2.9	2.8	3.0	3.5	3.2	684	3.1
Lip	-	-	-	-	-	-	-
Tongue	0.9	0.8	0.8	0.9	0.9	188	0.8
Salivary Gland	0.2	0.3	0.3	0.5	0.3	68	0.3
Floor of Mouth	-	-	-	-		-	-
Gum and Other Mouth	0.4	0.3	0.5	0.4	0.6	93	0.4
Nasopharynx	0.3	0.3	0.4	-	0.3	59	0.3
Tonsil	-	-	-	0.4	0.2	55	0.2
Oropharynx	0.3	0.3	-	0.3	0.2	57	0.3
Hypopharynx	-	-	-	=	-	30	0.1
Digestive System	56.9	56.2	55.5	55.8	54.2	11,799	55.7
Esophagus	6.4	6.5	7.8	7.3	7.0	1,526	7.0
Stomach	6.4	5.8	4.8	4.5	5.2	1,101	5.3
Small Intestine	0.5	0.5	0.4	0.4	0.3	88	0.4
Colon and Rectum	21.1	20.2	19.0	18.7	19.0	4,060	19.6
Colon excluding Rectum	17.7	16.5	15.6	15.1	15.1	3,284	16.0
Rectum and Rectosigmoid Junction	3.4	3.7	3.4	3.5	3.9	776	3.6
Anus, Anal Canal and Anorectum	_	_	-	-	-	38	0.2
Liver and Intrahepatic Bile Duct	7.4	8.3	8.3	8.9	8.3	1,827	8.3
Liver	6.2	6.2	6.6	6.7	6.3	1,432	6.4
Intrahepatic Bile Duct	1.2	2.1	1.8	2.2	2.1	395	1.9
Gallbladder	0.4	0.6	0.6	0.6	0.5	114	0.6
Pancreas	13.6	12.8	13.4	14.1	12.6	2,817	13.3
						Í	
Respiratory System	58.4	54.2	55.6	52.3	51.5	11,305	54.4
Larynx	2.2	1.8	1.9	2.2	1.5	418	1.9
Lung and Bronchus	55.8	52.3	53.5	49.6	49.4	10,814	52.0
						·	
Bones and Joints	0.3	0.5	0.4	0.5	0.4	94	0.4
Soft Tissue (Including Heart)	1.3	1.4	2.2	1.7	1.6	345	1.6
-							
Skin (Excluding Basal and Squamous)	4.9	4.8	4.7	4.6	5.2	999	4.8
Melanoma of the Skin	4.0	3.6	3.4	3.5	3.8	763	3.7

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 16 (continued). Age-adjusted Mortality Rates, Males, All Races Combined

a gu			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008	2012
Breast	0.4	0.3	0.6	0.2	0.3	75	0.4
Male Genital System	22.2	19.8	22.1	20.4	19.0	4,006	20.7
Prostate	21.9	19.5	21.8	19.8	18.8	3,928	20.3
Testis	0.3	-	-	0.4	-	50	0.2
Penis	-	-	-	-	-	22	0.1
Urinary System	14.3	13.8	14.7	13.6	13.9	2,836	14.1
Urinary Bladder	8.7	7.9	8.6	8.7	9.0	1,683	8.6
Kidney and Renal Pelvis	5.2	5.6	5.6	4.6	4.6	1,086	5.1
Ureter	-	-	-	-	-	21	0.1
Eye	-	-	_	-	-	21	0.1
Brain and Other Nervous System	4.7	4.6	4.7	4.6	5.2	1,030	4.8
Endocrine System	0.8	0.9	0.9	0.7	0.9	177	0.8
Thyroid	0.5	0.5	0.6	0.4	0.5	107	0.5
Lymphomas	7.8	8.0	8.1	7.5	7.8	1,592	7.8
Hodgkin Lymphoma	0.4	0.4	0.6	0.4	0.3	88	0.4
Non-Hodgkin Lymphoma	7.4	7.6	7.5	7.1	7.5	1,504	7.4
Multiple Myeloma	4.0	4.6	3.7	4.0	4.2	833	4.1
Leukemias	8.7	8.7	9.1	9.4	8.9	1,807	9.0
Lymphocytic Leukemia	2.3	2.3	2.6	2.8	2.5	512	2.5
Acute Lymphocytic Leukemia	0.5	0.4	0.5	0.3	0.5	92	0.4
Chronic Lymphocytic Leukemia	1.7	1.8	2.0	2.4	1.9	392	2.0
Myeloid and Monocytic Leukemia	3.5	3.5	4.1	4.2	3.8	786	3.8
Acute Myeloid Leukemia	2.8	3.1	3.4	3.6	3.3	667	3.3
Acute Monocytic Leukemia	-	=	-	=	-	-	-
Chronic Myeloid Leukemia	0.3	0.3	0.3	0.4	0.2	65	0.3
Other Leukemia	2.8	3.0	2.4	2.3	2.5	509	2.6
Ill-Defined & Unspecified Sites	18.3	18.5	17.4	16.8	15.4	3,544	17.3

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 17. Age-adjusted Mortality Rates, Females, All Races Combined

a au			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008-	-2012
All Sites	155.4	149.4	146.8	146.2	139.6	42,273	147.4
Oral Cavity and Pharynx	1.5	1.4	1.4	0.9	1.1	360	1.3
Lip	-	-	-	-	-	-	-
Tongue	0.3	0.5	0.4	0.3	0.4	106	0.4
Salivary Gland	-	-	0.3	-	-	42	0.1
Floor of Mouth	-	-	-	-	-	-	-
Gum and Other Mouth	0.4	0.2	0.2	-	0.3	70	0.2
Nasopharynx	0.2	-	0.3	-	-	43	0.2
Tonsil	-	-	-	-	-	16	0.1
Oropharynx	-	-	-	-	-	29	0.1
Hypopharynx	-	-	-	-	-	-	-
Digestive System	36.0	34.8	35.0	32.4	33.2	10,024	34.3
Esophagus	1.7	1.7	1.7	1.6	1.4	477	1.6
Stomach	3.1	3.0	3.0	2.4	2.6	813	2.8
Small Intestine	0.4	0.3	0.4	0.2	0.3	94	0.3
Colon and Rectum	15.0	14.0	13.8	13.0	13.1	4,113	13.8
Colon excluding Rectum	12.5	11.7	11.6	11.2	10.5	3,443	11.5
Rectum and Rectosigmoid Junction	2.5	2.3	2.2	1.8	2.6	670	2.3
Anus, Anal Canal and Anorectum	0.2	0.4	0.3	0.2	0.3	80	0.3
Liver and Intrahepatic Bile Duct	3.2	3.3	3.8	2.9	3.3	944	3.3
Liver	2.1	2.1	2.3	1.6	2.0	578	2.0
Intrahepatic Bile Duct	1.0	1.2	1.5	1.3	1.3	366	1.3
Gallbladder	1.0	0.7	1.1	0.6	0.8	245	0.8
Pancreas	10.3	10.5	10.1	10.1	10.3	2,977	10.3
Respiratory System	38.2	37.1	35.3	36.3	33.0	10,149	36.0
Larynx	0.5	0.5	0.6	0.5	0.4	150	0.5
Lung and Bronchus	37.5	36.4	34.5	35.7	32.4	9,951	35.3
Bones and Joints	0.4	0.3	0.3	0.5	-	83	0.3
Soft Tissue (Including Heart)	1.2	1.3	1.7	1.1	1.4	356	1.3
Skin (Excluding Basal and Squamous)	2.6	2.3	1.9	1.7	1.8	599	2.1
Melanoma of the Skin	2.1	1.7	1.5	1.3	1.4	463	1.6
Breast Pates are per 100 000 and age adjusted to the 2000 U.S.	25.6	24.0	23.2	24.3	22.6	6,787	23.9

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 17 (continued). Age-adjusted Mortality Rates, Females, All Races Combined

a au			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008	-2012
Female Genital System	16.6	16.6	17.8	17.3	16.1	4,748	16.9
Cervix Uteri	2.1	2.5	2.4	2.6	2.3	622	2.4
Corpus and Uterus, NOS	5.0	5.1	6.1	5.3	5.2	1,514	5.3
Corpus Uteri	1.9	2.1	2.4	2.2	2.0	594	2.1
Uterus, NOS	3.1	3.0	3.7	3.2	3.1	920	3.2
Ovary	8.7	8.0	8.5	8.4	7.7	2,338	8.3
Vagina	0.3	-	0.2	0.2	0.2	55	0.2
Vulva	0.4	0.5	0.5	0.4	0.6	151	0.5
Urinary System	4.9	4.8	4.9	4.6	4.6	1,422	4.8
Urinary Bladder	2.7	2.5	2.7	2.5	2.4	769	2.5
Kidney and Renal Pelvis	2.1	2.1	2.0	2.0	2.1	606	2.1
Ureter	-	-	-	-	-	26	0.1
Eye	-	-	-	-	-	-	-
Brain and Other Nervous System	2.6	2.9	3.0	3.3	2.8	791	2.9
Endocrine System	0.7	0.6	0.9	0.5	0.7	185	0.7
Thyroid	0.4	0.5	0.6	0.4	0.4	129	0.5
Lymphomas	5.6	4.9	4.5	5.1	4.7	1,445	4.9
Hodgkin Lymphoma	0.2	0.3	0.2	0.4	0.3	74	0.3
Non-Hodgkin Lymphoma	5.4	4.6	4.3	4.7	4.5	1,371	4.7
Multiple Myeloma	2.8	2.3	2.2	3.0	2.9	762	2.6
Leukemias	5.8	4.6	4.7	5.0	4.8	1,417	4.9
Lymphocytic Leukemia	1.3	1.1	1.4	1.0	1.2	354	1.2
Acute Lymphocytic Leukemia	0.4	0.3	0.3	0.3	0.3	86	0.3
Chronic Lymphocytic Leukemia	0.8	0.8	1.0	0.6	0.8	245	0.8
Myeloid and Monocytic Leukemia	2.7	2.1	2.2	2.6		656	
Acute Myeloid Leukemia	2.5	1.9	2.0	2.3	2.0	585	2.1
Acute Monocytic Leukemia	-	-	-	-	-	-	-
Chronic Myeloid Leukemia	-	-	-	0.2	-	42	0.1
Other Leukemia	1.7	1.4	1.1	1.4	1.3	407	1.4
Ill-Defined & Unspecified Sites	11.1	11.7	10.0	10.3	9.7	3,137	10.6

⁻ Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 18. Age-adjusted Mortality Rates, White Males

C Gu			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008	-2012
All Sites	205.7	199.4	203.3	198.6	195.9	34,928	200.5
Oral Cavity and Pharynx	2.9	2.6	2.7	3.5	3.1	541	3.0
Lip	-	-	-	-	-	-	-
Tongue	1.0	0.8	0.8	0.9	0.9	160	0.9
Salivary Gland	-	0.4	0.3	0.5	-	59	0.3
Floor of Mouth	-	-	-	-	-	-	-
Gum and Other Mouth	0.3	-	0.3	0.3	0.6	67	0.4
Nasopharynx	-	-	0.3	-	0.3	38	0.2
Tonsil	-	-	-	0.4	-	45	0.2
Oropharynx	0.3	-	-	0.3	-	44	0.2
Hypopharynx	-	-	-	-	-	22	0.1
Digestive System	55.3	56.1	54.2	55.9	54.7	9,791	55.3
Esophagus	6.7	6.8	7.8	8.0	7.6	1,337	7.4
Stomach	5.9	5.4	4.7	4.3	5.0	875	5.0
Small Intestine	0.5	0.6	0.4	0.4	0.4	80	0.5
Colon and Rectum	20.4	20.4	18.5	18.4	18.8	3,363	19.3
Colon excluding Rectum	16.9	16.5	15.1	14.8	14.9	2,711	15.6
Rectum and Rectosigmoid Junction	3.5	3.9	3.4	3.6	3.9	652	3.6
Anus, Anal Canal and Anorectum	-	-	-	-	-	32	0.2
Liver and Intrahepatic Bile Duct	6.7	8.0	7.9	8.9	8.2	1,446	7.9
Liver	5.5	5.9	6.0	6.5	6.1	1,101	6.0
Intrahepatic Bile Duct	1.2	2.2	1.9	2.3	2.1	345	2.0
Gallbladder	0.4	0.6	0.5	0.7	0.6	94	0.5
Pancreas	13.7	12.8	13.3	14.0	12.9	2,374	13.4
Respiratory System	58.6	54.5	57.1	53.0	52.8	9,645	55.1
Larynx	2.3	1.9	1.9	2.1	1.6	348	1.9
Lung and Bronchus	55.9	52.4	54.9	50.6	50.6	9,234	52.8
Bones and Joints	0.4	0.6	0.5	0.5	0.4	81	0.5
Soft Tissue (Including Heart)	1.4	1.4	2.3	1.8	1.9	301	1.8
Skin (Excluding Basal and Squamous)	5.5	5.5	5.4	5.4	6.0	967	5.6
Melanoma of the Skin	4.6	4.2	3.9	4.2	4.3	741	4.2

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.
- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 18 (continued). Age-adjusted Mortality Rates, White Males

G G'4-			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008	-2012
Breast	0.4	0.3	0.5	-	0.3	62	0.3
Male Genital System	20.7	17.8	19.9	18.9	17.1	3,162	18.9
Prostate	20.4	17.5	19.5	18.2	16.7	3,092	18.4
Testis	0.3	-	-	0.4	-	47	0.3
Penis	-	-	-	-	-	18	0.1
Urinary System	14.8	14.5	15.6	14.5	14.9	2,555	14.9
Urinary Bladder	9.2	8.4	9.1	9.3	9.8	1,549	9.2
Kidney and Renal Pelvis	5.3	5.8	5.9	4.9	4.8	948	5.4
Ureter	-	-	-	-	-	17	0.1
Eye						10	0.1
Eye	-	-	-	-	-	18	0.1
Brain and Other Nervous System	5.1	5.1	5.2	5.0	5.7	921	5.2
Endocrine System	0.8	0.8	1.0	0.8	0.9	151	0.8
Thyroid	0.5	0.5	0.7	0.4	0.5	96	0.5
Lymphomas	8.3	8.4	8.4	8.0	8.3	1,424	8.3
Hodgkin Lymphoma	0.5	0.5	0.6	0.4	0.3	78	0.5
Non-Hodgkin Lymphoma	7.8	7.9	7.8	7.6	8.0	1,346	7.8
Multiple Myeloma	3.7	4.0	3.6	3.7	4.1	655	3.8
Leukemias	9.1	9.3	9.7	10.2	9.7	1,637	9.6
Lymphocytic Leukemia	2.5	2.4	2.8	3.1	2.6	461	2.7
Acute Lymphocytic Leukemia	0.5	0.3	0.5	0.3	0.5	73	0.4
Chronic Lymphocytic Leukemia	1.8	2.0	2.1	2.6	1.9	362	2.1
Myeloid and Monocytic Leukemia	3.8	3.8	4.5	4.6	4.3	721	4.2
Acute Myeloid Leukemia	3.1	3.5	3.8	3.8	3.8	616	3.6
Acute Monocytic Leukemia	-	-	-	-	-	-	-
Chronic Myeloid Leukemia	0.3	-	0.4	0.5	-	56	0.3
Other Leukemia	2.8	3.1	2.4	2.6	2.8	455	2.7
Ill-Defined & Unspecified Sites	18.4	18.3	17.3	16.9	16.2	3,017	17.4

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 19. Age-adjusted Mortality Rates, White Females

Campan Sita			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008	-2012
All Sites	158.7	152.9	148.7	147.8	143.3	35,926	150.3
Oral Cavity and Pharynx	1.6	1.5	1.5	0.8	1.1	312	1.3
Lip	-	-	-	-	-	-	-
Tongue	0.3	0.6	0.5	0.2	0.4	94	0.4
Salivary Gland	-	-	0.3	-	-	38	0.2
Floor of Mouth	-	-	-	-	-	-	-
Gum and Other Mouth	0.4	0.2	-	-	0.3	62	0.2
Nasopharynx	0.2	-	0.3	-	-	33	0.1
Tonsil	-	-	-	-	-	13	0.1
Oropharynx	-	-	-	-	ı	25	0.1
Hypopharynx	-	-	-	-	-	-	-
Digestive System	35.6	34.0	34.3	32.6	32.8	8,368	33.9
Esophagus	1.7	1.8	1.6	1.7	1.4	401	1.6
Stomach	2.8	2.7	2.6	2.5	2.3	630	2.6
Small Intestine	0.3	0.3	0.4	0.2	0.3	74	
Colon and Rectum	14.6	13.6	13.5	12.9	13.2	3,442	13.6
Colon excluding Rectum	12.2	11.2	11.3	11.1	10.6	2,881	11.3
Rectum and Rectosigmoid Junction	2.5	2.4	2.3	1.8	2.6	561	2.3
Anus, Anal Canal and Anorectum	0.2	0.5	0.3	_	0.3	69	0.3
Liver and Intrahepatic Bile Duct	3.2	3.3	3.8	2.9	3.3	787	3.3
Liver	2.1	2.2	2.4	1.6	2.0	488	2.1
Intrahepatic Bile Duct	1.1	1.1	1.4	1.3	1.3	299	
Gallbladder	1.1	0.7	1.1	0.6	0.8	207	
Pancreas	10.6	10.3	10.1	10.3	10.2	2,519	10.3
Respiratory System	39.9	39.0	37.2	37.8	35.0	8,849	37.8
Larynx	0.4	0.6	0.5	0.5	0.4	116	
Lung and Bronchus	39.3	38.2	36.5	37.1	34.4	8,688	37.1
Bones and Joints	0.5	0.3	0.3	0.4	-	69	0.4
Soft Tissue (Including Heart)	1.1	1.3	1.8	1.2	1.4	294	1.3
Skin (Excluding Basal and Squamous)	3.0	2.6	2.2	2.0	2.1	578	2.4
Melanoma of the Skin	2.4	2.0	1.8	1.6	1.8	449	1.9
Breast	25.6	24.0	22.7	23.9	22.5	5,566	23.7

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 19 (continued). Age-adjusted Mortality Rates, White Females

G G''			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008	-2012
Female Genital System	16.7	16.9	18.0	17.1	16.0	3,929	16.9
Cervix Uteri	2.1	2.4	2.1	2.3	2.4	464	2.2
Corpus and Uterus, NOS	4.6	4.6	6.0	4.9	4.8	1,179	5.0
Corpus Uteri	1.9	1.9	2.3	2.1	1.7	467	2.0
Uterus, NOS	2.7	2.7	3.6	2.8	3.0	712	3.0
Ovary	9.2	8.8	9.0	8.9	8.0	2,042	8.8
Vagina	0.2	-	0.2	-	-	43	0.2
Vulva	0.5	0.6	0.5	0.4	0.7	142	0.5
Urinary System	5.1	5.1	5.1	4.7	5.1	1,265	5.0
Urinary Bladder	2.8	2.7	2.8	2.7	2.6	692	2.7
Kidney and Renal Pelvis	2.2	2.3	2.1	1.9	2.3	535	
Ureter	-	-	-	-	-	24	0.1
Eye	-	-	-	-	-	-	-
Brain and Other Nervous System	2.9	3.3	3.1	3.6	3.1	713	3.2
Endocrine System	0.7	0.7	0.8	0.4	0.7	148	0.7
Thyroid	0.4	0.5	0.6	0.3	0.4	106	0.5
Lymphomas	5.9	5.2	4.6	5.3	5.2	1,296	5.2
Hodgkin Lymphoma	-	0.3	0.2	0.4	0.3	62	0.3
Non-Hodgkin Lymphoma	5.7	4.9	4.4	4.9	4.9	1,234	5.0
Multiple Myeloma	2.8	2.2	1.9	2.6	2.8	605	2.5
Leukemias	6.2	5.0	4.8	5.1	5.1	1,253	5.2
Lymphocytic Leukemia	1.4	1.3	1.5	1.1	1.3	322	1.3
Acute Lymphocytic Leukemia	0.4	0.4	0.4	0.3	0.3	75	
Chronic Lymphocytic Leukemia	0.4	0.4	1.1	0.3	0.3	226	
Myeloid and Monocytic Leukemia	2.9	2.3		2.7	2.5	583	
Acute Myeloid Leukemia	2.9	2.3	2.2	2.7	2.3	520	2.3
Acute Monocytic Leukemia	2.7	2.1	2.0	2.4	۷.۷	320	2.3
Chronic Myeloid Leukemia	-	_	-		-	38	0.1
Other Leukemia	1.9	1.4	1.1	1.3	1.3	348	
Ouici Leukeiiiia	1.9	1.4	1.1	1.3	1.3	340	1.4
Ill-Defined & Unspecified Sites	11.2	12.0	10.2	10.3	10.0	2,673	10.7

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.
- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 20. Age-adjusted Mortality Rates, Black Males

C			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008	-2012
All Sites	269.3	259.8	258.0	230.1	224.1	5,072	247.4
Oral Cavity and Pharynx	4.2	5.0	5.1	4.5	3.5	109	4.4
Lip	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	22	0.9
Salivary Gland	-	-	-	-	-	-	-
Floor of Mouth	-	-	-	-	-	-	-
Gum and Other Mouth	-	-	-	-	-	13	0.6
Nasopharynx	-	-	-	-	-	14	0.5
Tonsil	-	-	-	-	-	-	-
Oropharynx	-	-	_	-	-	13	0.5
Hypopharynx	-	-	-	-	=	-	-
Digestive System	81.9	70.3	79.0	67.0	64.0	1,577	72.1
Esophagus	6.8	7.6	10.2	5.3	4.6	155	6.9
Stomach	10.4	9.1	5.9	5.7	7.8	158	7.7
Small Intestine	-	-	-	-	-	-	-
Colon and Rectum	32.9	24.5	28.5	28.4	27.4	581	28.2
Colon excluding Rectum	28.7	21.2	23.2	23.7	21.7	477	23.6
Rectum and Rectosigmoid Junction	4.2	3.3	5.2	4.6	5.6	104	4.6
Anus, Anal Canal and Anorectum	-	-	_	-	-	-	_
Liver and Intrahepatic Bile Duct	13.4	11.0	13.8	8.6	8.1	274	10.9
Liver	11.2	9.5	12.4	7.1	7.1	244	9.4
Intrahepatic Bile Duct	-	-	_	-	-	30	1.5
Gallbladder	-	-	-	-	-	13	0.8
Pancreas	15.8	15.4	16.7	16.6	14.6	354	15.8
Respiratory System	74.5	72.6	61.1	58.5	59.4	1,366	64.9
Larynx	3.5	2.5	2.8	3.5	-	59	2.8
Lung and Bronchus	70.5	70.1	57.8	54.6	57.6	1,300	61.8
Bones and Joints	-	-	-	-	-	11	0.4
Soft Tissue (Including Heart)	-	-	1.8	1.9	_	37	1.4
Skin (Excluding Basal and Squamous)	_					25	1.0
Melanoma of the Skin	_					16	0.6

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 20 (continued). Age-adjusted Mortality Rates, Black Males

G			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008	-2012
Breast	-	-	-	-	-	-	
Male Genital System	45.4	47.2	53.0	42.3	47.4	791	47.0
Prostate	45.1	46.8	52.8	42.0	47.2	783	46.8
Testis	-	-	-	-	-	-	
Penis	-	-	-	-	-	-	
Urinary System	12.6	10.9	9.7	9.7	11.4	216	10.9
Urinary Bladder	6.1	4.7	4.7	5.1	7.3	102	5.6
Kidney and Renal Pelvis	6.1	6.0	4.5	4.6	4.2	109	5.1
Ureter	-	-	-	-	-	-	
Eye	_	_	_	_	-	_	
•							
Brain and Other Nervous System	3.4	2.9	2.6	3.5	3.9	77	3.3
Endocrine System	-	-	-	-	-	15	0.7
Thyroid	-	-	-	-	-	-	
Lymphomas	4.8	6.9	7.3	5.5	5.0	126	5.9
Hodgkin Lymphoma	-	-	-	-	-	-	
Non-Hodgkin Lymphoma	4.8	6.4	6.9	5.0	4.6	117	5.6
Multiple Myeloma	8.1	10.9	4.7	7.0	6.5	150	7.4
Leukemias	7.3	6.1	7.6	6.4	5.4	133	6.6
Lymphocytic Leukemia	-	-	-	-	2.8	37	2.0
Acute Lymphocytic Leukemia	-	-	-	-	-	10	0.4
Chronic Lymphocytic Leukemia	-	-	-	-	-	26	1.5
Myeloid and Monocytic Leukemia	2.7	-	2.9	3.4	-	55	2.5
Acute Myeloid Leukemia	-	-	-	3.0	-	42	1.9
Acute Monocytic Leukemia	-	-	-	-	-	-	
Chronic Myeloid Leukemia	-	-	-	-	-	-	
Other Leukemia	2.5	2.7	2.9	-	-	41	2.1
Ill-Defined & Unspecified Sites	23.5	23.1	22.7	21.9	14.4	428	21.0

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 21. Age-adjusted Mortality Rates, Black Females

Comment State			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008	2012
All Sites	166.2	159.8	164.3	167.2	150.3	5,230	161.4
Oral Cavity and Pharynx	-	-	-	-	-	35	1.0
Lip	-	-	-	-	-	-	-
Tongue	-	-	-	-	-	-	-
Salivary Gland	-	-	-	-	-	-	-
Floor of Mouth	-	-	-	-	-	-	-
Gum and Other Mouth	-	-	-	-	-	-	-
Nasopharynx	-	-	-	-	-	-	-
Tonsil	-	-	-	-	-	-	-
Oropharynx	-	-	-	-	-	-	-
Hypopharynx	-	-	-	-	-	-	-
Digestive System	43.9	45.0	45.1	37.2	40.8	1,343	42.3
Esophagus	2.3	2.0	1.9	-	2.1	64	1.9
Stomach	4.6	4.2	6.0	2.8	3.8	132	4.3
Small Intestine	-	-	-	-	-	16	0.5
Colon and Rectum	19.7	19.6	17.0	17.3	15.6	563	17.8
Colon excluding Rectum	16.1	16.6	14.7	15.1	12.7	476	15.0
Rectum and Rectosigmoid Junction	3.6	3.0	2.3	2.2	2.9	87	2.8
Anus, Anal Canal and Anorectum	_	-	_	-	-	10	0.3
Liver and Intrahepatic Bile Duct	3.4	3.6	4.3	2.5	3.3	111	3.4
Liver	2.2	1.7	2.7	-	1.9	63	2.0
Intrahepatic Bile Duct	-	1.8	1.7	-	1.4	48	1.4
Gallbladder	-	-	-	-	-	25	0.7
Pancreas	11.1	13.4	12.8	10.9	13.9	392	12.4
Respiratory System	38.6	33.1	32.3	36.5	29.7	1,096	34.0
Larynx	1.5	33.1	1.5	50.5	27.1	34	1.0
Lung and Bronchus	36.9	32.7	30.8	35.7	29.0	1,061	32.9
Bones and Joints	-	-	-	-	-	-	-
Soft Tissue (Including Heart)	2.2	1.5	-	-	1.6	52	1.5
Skin (Excluding Basal and Squamous)	_	_	_	_	_	13	0.4
Melanoma of the Skin	-	-	-	-	-	-	-
Breast	29.5	30.4	31.1	33.2	28.1	1,025	30.4
Potes are per 100 000 and age adjusted to the 2000 I			31.1	33.2	28.1	1,025	30.

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 21 (continued). Age-adjusted Mortality Rates, Black Females

Company Site			Rates			Cases	Rates
Cancer Site	2008	2009	2010	2011	2012	2008	-2012
Female Genital System	18.6	18.9	20.0	21.2	21.4	663	20.1
Cervix Uteri	2.0	3.3	5.0	4.8	3.4	130	3.7
Corpus and Uterus, NOS	7.8	9.7	8.2	9.2	8.4	282	8.6
Corpus Uteri	1.8	3.8	3.1	3.0	3.8	101	3.1
Uterus, NOS	6.0	5.9	5.0	6.2	4.6	181	5.5
Ovary	7.5	4.9	6.6	6.5	8.9	224	6.9
Vagina	_	-	-	-	-	10	0.3
Vulva	-	-	-	-	-	-	-
Urinary System	4.8	4.4	4.7	5.6	3.3	140	4.6
Urinary Bladder	2.6	2.2	2.8	2.0	1.9	69	2.3
Kidney and Renal Pelvis	2.0	1.9	1.6	3.4	-	63	2.0
Ureter	-	-	-	-	-	-	-
Eye	-	-	-	-	-	-	-
Brain and Other Nervous System	-	-	2.2	2.8	1.5	56	1.7
Endocrine System	-	-	-	-	_	27	0.8
Thyroid	-	-	-	-	-	15	0.5
Lymphomas	3.9	2.8	4.1	4.2	2.4	112	3.5
Hodgkin Lymphoma	-	-	-	-	-	12	0.3
Non-Hodgkin Lymphoma	3.4	2.6	3.9	3.4	2.4	100	3.1
Multiple Myeloma	3.7	3.0	5.3	6.1	4.4	141	4.5
Leukemias	4.7	3.1	4.5	3.9	3.9	124	4.0
Lymphocytic Leukemia	_	-	-	-	_	26	0.8
Acute Lymphocytic Leukemia	_	-	-	-	-	-	_
Chronic Lymphocytic Leukemia	-	-	-	-	-	17	0.6
Myeloid and Monocytic Leukemia	2.4	_	2.0	1.8	1.6		
Acute Myeloid Leukemia	2.2	-	1.9	-	1.6	51	1.6
Acute Monocytic Leukemia	-	-	-	-	-	-	_
Chronic Myeloid Leukemia	-	-	-	-	-	-	_
Other Leukemia	-	-	-	-	1.5	43	1.4
Ill-Defined & Unspecified Sites Rates are per 100 000 and age-adjusted to the 2000 U	13.2	14.2	11.0	13.0	10.9	394	12.4

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 22. Age-adjusted Mortality Rates, Hispanic Males and Females, **2008-2012 Combined**

Cancer Site	Ma	ale	Fen	nale
Cancer Site	Rate	Cases	Rate	Cases
All Sites	131.1	2,419	87.8	2,246
Oral Cavity and Pharynx	1.7	37	0.7	17
Lip	-	-	-	_
Tongue	0.4	10	-	_
Salivary Gland	-	-	-	_
Floor of Mouth	-	-	-	_
Gum and Other Mouth	-	-	-	-
Nasopharynx	-	-	-	-
Tonsil	-	-	-	-
Oropharynx	_	-	-	_
Hypopharynx	-	-	-	-
Digestive System	44.2	863	27.0	654
Esophagus	4.2	77	0.9	22
Stomach	7.2	137	3.9	96
Small Intestine	0.7	12	-	_
Colon and Rectum	13.2	253	9.0	223
Colon excluding Rectum	11.2	213	7.5	183
Rectum and Rectosigmoid Junction	1.9	40	1.6	40
Anus, Anal Canal and Anorectum	-	-	-	_
Liver and Intrahepatic Bile Duct	8.9	192	3.5	83
Liver	7.2	161	2.4	57
Intrahepatic Bile Duct	1.7	31	1.1	26
Gallbladder	0.8	13	1.0	25
Pancreas	8.3	163	7.3	169
Respiratory System	30.1	538	11.2	276
Larynx	2.1	39	0.5	11
Lung and Bronchus	27.6	493	10.7	264
Bones and Joints	_	-	-	-
Soft Tissue (Including Heart)	1.0	23	0.8	26
Soft Tissue (including Heart)	1.0	23	0.8	20
Skin (Excluding Basal and Squamous)	0.8	15	0.5	14
Melanoma of the Skin	0.7	12	-	-
Breast	-	-	13.1	371

⁻ Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 22 (continued). Age-adjusted Mortality Rates, Hispanic Males and Females, 2008-2012 Combined

Cancer Site	Ma	ale	Female		
ancer site	Rate	Cases	Rate	Cases	
Female Genital System	*	*	12.1	323	
Cervix Uteri	*	*	2.7	81	
Corpus and Uterus, NOS	*	*	3.9	99	
Corpus Uteri	*	*	1.5	39	
Uterus, NOS	*	*	2.4	60	
Ovary	*	*	4.7	126	
Vagina	*	*	-	-	
Vulva	*	*	-	-	
Male Genital System	15.1	215	*	*	
Prostate	14.5	200	*	k	
Testis	-	-	*	*	
Penis	-	-	*	*	
Urinary System	7.9	133	2.6	60	
Urinary Bladder	4.9	71	1.4	32	
Kidney and Renal Pelvis	3.0	61	1.1	27	
Ureter	-	0	=	-	
Eye	-	-	-		
Brain and Other Nervous System	2.8	78	1.9	55	
Endocrine System	0.7	15	-	-	
Thyroid	-	-	-	_	
Lymphomas	6.7	132	3.7	91	
Hodgkin Lymphoma	-	-	1	-	
Non-Hodgkin Lymphoma	6.4	123	3.5	88	
Multiple Myeloma	3.1	55	2.5	58	
Leukemias	5.8	114	3.9	104	
Lymphocytic Leukemia	1.5	31	0.8	25	
Acute Lymphocytic Leukemia	0.5	14	0.5	18	
Chronic Lymphocytic Leukemia	1.0	15	_	-	
Myeloid and Monocytic Leukemia	2.6	54	1.9	50	
Acute Myeloid Leukemia	1.9	41	1.8	46	
Acute Monocytic Leukemia	-	-	-	-	
Chronic Myeloid Leukemia	-	-	_		
Other Leukemia	1.6	29	1.2	29	
Ill-Defined & Unspecified Sites	10.9	192	7.4	180	

Note: Hispanic includes all races.

^{*} Non-applicable gender

⁻ Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 23. Age-adjusted Mortality Rates, Asian and Pacific Islander Males and Females, 2008-2012 Combined

G	Ma	le	Female			
Cancer Site	Rate	Cases	Rate	Cases		
All Sites	97.1	1,115	73.7	1,077		
Oral Cavity and Pharynx	2.7	34	1.0	13		
Lip	-	-	-	-		
Tongue	-	-	-	-		
Salivary Gland	-	-	-	-		
Floor of Mouth	-	-	-	-		
Gum and Other Mouth	1.1	13	-	-		
Nasopharynx	-	-	-	-		
Tonsil	-	-	-	-		
Oropharynx	-	-	-	-		
Hypopharynx	-	-	-	-		
Digestive System	35.1	421	21.7	303		
Esophagus	2.5	32	0.9	11		
Stomach	5.4	66	3.6	51		
Small Intestine	-	-	-	-		
Colon and Rectum	9.6	112	7.5	103		
Colon excluding Rectum	8.0	92	6.0	82		
Rectum and Rectosigmoid Junction	1.6	20	1.4	21		
Anus, Anal Canal and Anorectum	_	-	-	-		
Liver and Intrahepatic Bile Duct	8.5	107	3.2	46		
Liver	6.8	87	1.9	27		
Intrahepatic Bile Duct	1.7	20	1.3	19		
Gallbladder	_	-	0.7	12		
Pancreas	8.1	87	4.5	63		
Respiratory System	25.8	289	13.9	191		
Larynx	0.9	10	13.7	171		
Lung and Bronchus	24.6	276	13.7	189		
Bones and Joints						
Dones and Joints	-	-	-	-		
Soft Tissue (Including Heart)	-	-	-	-		
Skin (Excluding Basal and Squamous)	_	_	_	_		
Melanoma of the Skin	-	-	-	-		
Breast			11.3	189		

⁻ Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 23 (continued). Age-adjusted Mortality Rates, Asian and Pacific Islander Males and Females, 2008-2012 Combined

Cancer Site	Ma	ale	Fen	Female		
ancer Site	Rate	Cases	Rate	Cases		
Female Genital System	*	*	9.0	152		
Cervix Uteri	*	*	1.6	27		
Corpus and Uterus, NOS	*	*	3.0	51		
Corpus Uteri	*	*	1.6	26		
Uterus, NOS	*	*	1.5	25		
Ovary	*	*	4.2	71		
Vagina	*	*	-	-		
Vulva	*	*	-	-		
Male Genital System	6.1	51	*	*		
Prostate	6.1	51	*	*		
Testis	_	-	*	*		
Penis	-	-	*	*		
Urinary System	5.5	58	1.2	16		
Urinary Bladder	3.1	26	1.2	10		
Kidney and Renal Pelvis	2.1	28	_	<u>.</u>		
Ureter	-	-	-			
Eye	-	-	-			
Brain and Other Nervous System	1.9	31	1.4	21		
Endocrine System	1.1	11	0.8	10		
Thyroid	-	-	-	-		
Lymphomas	3.6	41	2.6	37		
Hodgkin Lymphoma	-	-	-	-		
Non-Hodgkin Lymphoma	3.5	40	2.6	37		
Multiple Myeloma	2.5	27	1.1	16		
Leukemias	3.1	37	3.1	40		
Lymphocytic Leukemia	1.0		-			
Acute Lymphocytic Leukemia	_	-	-	-		
Chronic Lymphocytic Leukemia	_	_	_	-		
Myeloid and Monocytic Leukemia	0.9	10	1.3	18		
Acute Myeloid Leukemia	-	-	1.0	14		
Acute Monocytic Leukemia	-	-	-	-		
Chronic Myeloid Leukemia	_	-	-	-		
Other Leukemia	1.3	13	1.3	16		
Ill-Defined & Unspecified Sites	8.0	94	5.2	67		

^{*} Non-applicable gender

⁻ Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 24. Comparative Mortality Rates, New Jersey and U.S., Males, 2008-2012

Cancer Site		New.	Jersey 20	008-201	2	United States 2008-2012					
Population:	All Races White Black		API*	Hispanic*	All Races	White	Black	API*	Hispanic*		
All Sites	199.0 200.5 247.4 97.1		131.1	207.9	206.4	261.5	128.4	148.0			
Lung	52.0	52.8	61.8	24.6	27.6	59.8	59.7	73.1	34.0	29.5	
Prostate	20.3	18.4	46.8	6.1	14.5	21.4	19.8	46.3	9.4	17.8	
Colorectal	19.6 19.3 28.2 9.6				13.2	18.6	18.0	26.9	13.0	15.6	

^{*}API=Asians and pacific Islanders; Hispanic includes all races.

Table 25. Comparative Mortality Rates, New Jersey and U.S., Females, 2008-2012

Cancer Site		New.	Jersey 20	008-201	2	United States 2008-2012						
Population:	All Races White Black API* Hispanic*		All Races	White	Black	API*	Hispanic*					
All Sites	147.4 150.3 161.4 73.7		87.8	145.4	145.6	166.3	91.2	99.4				
Lung	35.3	37.1	32.9	13.7	10.7	37.8	39.1	35.8	18.2	13.7		
Breast	23.9	23.7	30.4	11.3	13.1	21.9	21.3	30.2	11.4	14.5		
Colorectal	13.8	13.6	17.8	7.5	9.0	13.1	12.7	17.8	9.4	9.6		

^{*}API=Asians and pacific Islanders; Hispanic includes all races.

<u>Cancer Incidence and Mortality in New Jersey, 2008-2012</u>
Table 26. Population Denominators by Race, Age Group and Year

			Male				Female						
	2008-12	2008	2009	2010	2011	2012	2008-12	2008	2009	2010	2011	2012	
<1	272,674	55,368	54,336	53,835	54,906	54,229	260,799	53,356	51,927	51,571	52,214	51,731	
01-04	1,108,222	223,884	222,005	222,170	220,446	219,717	1,062,401	213,899	212,995	213,145	211,818	210,544	
05-09	1,436,633	286,772	289,149	288,043	286,501	286,168	1,374,299	273,585	276,336	275,657	274,365	274,356	
10-14	1,499,547	303,325	301,139	299,981	298,789	296,313	1,431,283	289,428	287,355	286,669	285,159	282,672	
15-19	1,542,868	311,834	311,238	309,288	307,404	303,104	1,445,869	292,076	290,724	289,004	288,354	285,711	
20-24	1,396,596	270,734	275,079	279,947	283,505	287,331	1,306,030	253,175	257,864	262,239	264,431	268,321	
25-29	1,400,945	276,022	277,812	278,780	282,725	285,606	1,376,266	272,506	274,464	275,756	276,793	276,747	
30-34	1,386,169	272,457	273,201	276,406	280,393	283,712	1,407,581	275,740	278,132	282,059	284,759	286,891	
35-39	1,446,472	303,556	296,477	287,938	280,479	278,022	1,489,340	313,945	306,339	296,980	287,815	284,261	
40-44	1,592,958	330,080	321,560	316,848	314,318	310,152	1,662,739	345,210	336,276	331,146	327,744	322,363	
45-49	1,704,577	345,942	346,353	343,962	337,818	330,502	1,782,977	360,021	361,102	359,338	354,134	348,382	
50-54	1,635,623	314,557	322,289	329,348	333,773	335,656	1,722,706	331,620	340,795	347,547	351,091	351,653	
55-59	1,373,644	258,174	266,203	274,447	282,677	292,143	1,482,931	281,672	287,772	295,722	303,949	313,816	
60-64	1,130,151	209,679	218,585	228,766	237,295	235,826	1,260,598	234,568	244,474	255,419	264,580	261,557	
65-69	824,998	153,000	157,656	163,030	168,683	182,629	964,075	179,516	185,659	190,865	196,378	211,657	
70-74	584,796	111,972	114,310	116,151	118,670	123,693	732,325	141,791	143,195	145,319	148,149	153,871	
75-79	454,642	92,814	91,064	90,123	90,116	90,525	627,037	129,363	126,866	124,829	123,325	122,654	
80-84	346,014	68,695	69,018	69,685	69,513	69,103	548,211	111,887	110,720	109,657	108,669	107,278	
85+	283,595	52,324	54,622	56,904	58,866	60,879	615,196	116,543	120,511	124,133	126,035	127,974	
Total	21,421,124	4,241,189	4,262,096	4,285,652	4,306,877	4,325,310	22,552,663	4,469,901	4,493,506	4,517,055	4,529,762	4,542,439	

White

			Male						Female			
	2008-12	2008	2009	2010	2011	2012	2008-12	2008	2009	2010	2011	2012
<1	190,690	39,003	37,978	37,727	38,295	37,687	181,890	37,371	36,082	36,053	36,470	35,914
01-04	785,370	161,307	158,401	157,084	154,945	153,633	749,426	153,633	151,206	149,890	148,171	146,526
05-09	1,036,317	208,581	209,362	207,665	205,988	204,721	985,083	197,338	198,910	197,595	196,083	195,157
10-14	1,092,505	221,889	220,090	218,659	217,100	214,767	1,035,603	210,907	208,531	207,268	205,573	203,324
15-19	1,123,418	228,506	226,641	224,367	223,428	220,476	1,043,472	211,556	209,840	207,969	208,061	206,046
20-24	1,009,973	197,120	200,272	203,065	204,144	205,372	927,705	181,511	184,459	186,523	186,703	188,509
25-29	1,009,944	199,245	200,760	201,541	203,457	204,941	954,144	188,530	190,000	191,556	192,005	192,053
30-34	984,683	194,542	194,186	196,193	198,885	200,877	960,837	189,475	190,071	192,193	193,905	195,193
35-39	1,037,844	222,020	214,539	206,176	198,961	196,148	1,040,667	224,084	216,206	207,198	198,508	194,671
40-44	1,192,139	251,004	242,904	237,241	233,346	227,644	1,216,383	257,069	248,410	242,311	237,714	230,879
45-49	1,317,792	271,221	269,381	265,920	259,275	251,995	1,350,664	276,767	275,130	272,362	266,333	260,072
50-54	1,293,765	251,254	256,176	260,022	262,920	263,393	1,334,214	259,025	265,037	268,794	271,023	270,335
55-59	1,106,944	209,236	215,096	221,713	227,266	233,633	1,165,748	222,533	226,878	232,832	238,429	245,076
60-64	923,587	172,611	179,403	186,860	193,558	191,155	1,003,825	188,549	195,835	203,411	209,966	206,064
65-69	676,013	125,426	129,269	133,470	137,917	149,931	775,603	144,735	149,357	153,485	157,701	170,325
70-74	479,196	92,666	94,076	95,084	96,732	100,638	592,442	115,982	116,435	117,339	119,168	123,518
75-79	387,743	80,686	78,483	76,930	76,001	75,643	526,938	110,984	107,620	104,964	102,426	100,944
80-84	307,938	61,763	61,823	62,121	61,600	60,631	481,688	99,492	97,910	96,433	94,935	92,918
85+	258,052	47,900	49,896	51,817	53,407	55,032	556,273	106,187	109,335	112,321	113,624	114,806
Total	16,213,913	3,235,980	3,238,736	3,243,655	3,247,225	3,248,317	16,882,605	3,375,728	3,377,252	3,380,497	3,376,798	3,372,330

DI	٦	_	1
1)	ıa	L.	r

	Male						Female					
	2008-12	2008	2009	2010	2011	2012	2008-12	2008	2009	2010	2011	2012
<1	50,464	10,073	9,896	9,891	10,273	10,331	48,766	9,736	9,669	9,546	9,860	9,955
01-04	197,294	38,915	39,131	39,636	39,675	39,937	190,060	37,212	37,690	38,316	38,326	38,516
05-09	247,211	49,444	49,895	49,673	49,134	49,065	238,397	47,739	47,958	47,827	47,418	47,455
10-14	266,152	54,648	53,638	53,044	52,733	52,089	257,728	52,482	51,880	51,575	51,303	50,488
15-19	286,177	58,077	58,408	58,008	56,675	55,009	277,168	57,071	56,687	55,966	54,346	53,098
20-24	257,490	48,768	49,398	51,029	53,117	55,178	254,835	48,066	49,211	50,995	52,556	54,007
25-29	223,373	44,606	44,276	43,961	44,834	45,696	241,825	48,909	48,480	47,903	48,207	48,326
30-34	212,354	40,791	41,658	42,652	43,365	43,888	242,555	46,863	47,861	48,959	49,297	49,575
35-39	215,017	44,794	43,977	42,978	41,789	41,479	249,178	51,940	51,320	49,819	48,354	47,745
40-44	232,690	47,782	46,621	46,251	46,128	45,908	267,750	54,847	53,449	53,310	53,230	52,914
45-49	234,655	46,187	47,102	47,427	47,240	46,699	271,276	52,990	54,415	54,701	54,672	54,498
50-54	209,058	38,810	40,353	42,349	43,343	44,203	244,761	45,989	47,666	49,522	50,411	51,173
55-59	158,894	29,414	30,682	31,391	32,738	34,669	199,233	37,880	38,628	39,531	40,718	42,476
60-64	121,475	22,203	23,186	24,597	25,617	25,872	162,053	29,376	30,901	32,753	34,322	34,701
65-69	87,435	16,555	16,845	17,433	17,805	18,797	121,676	23,291	23,873	24,150	24,509	25,853
70-74	62,741	12,006	12,359	12,527	12,740	13,109	93,817	17,826	18,203	18,827	19,201	19,760
75-79	42,297	8,072	8,203	8,396	8,717	8,909	70,122	13,250	13,767	13,958	14,445	14,702
80-84	25,716	4,859	4,968	5,137	5,262	5,490	48,120	9,213	9,392	9,583	9,812	10,120
85+	17,296	3,060	3,249	3,476	3,665	3,846	44,808	7,952	8,637	9,054	9,359	9,806
Total	3,147,789	619,064	623,845	629,856	634,850	640,174	3,524,128	692,632	699,687	706,295	710,346	715,168

"Hispanic includes all races.
Source: The National Cancer Institute's SEER Program (URL: http://www.seer.cancer.gov/popdata/index.html).

<u>Cancer Incidence and Mortality in New Jersey, 2008-2012</u> Table 26 (continued). Population Denominators by Race, Age Group and Year

Asian and Pacific Islander

	Male						Female					
_	2008-12	2008	2009	2010	2011	2012	2008-12	2008	2009	2010	2011	2012
<1	29,327	6,003	5,974	5,688	6,006	5,656	27,989	5,949	5,660	5,467	5,591	5,322
01-04	115,631	21,990	22,632	23,228	23,600	24,181	113,578	21,507	22,355	22,875	23,237	23,604
05-09	141,564	26,705	27,695	28,397	28,950	29,817	139,433	26,520	27,337	27,933	28,463	29,180
10-14	129,723	24,717	25,228	26,002	26,646	27,130	127,207	23,995	24,784	25,613	26,126	26,689
15-19	121,129	22,921	23,757	24,429	24,855	25,167	114,073	21,384	22,034	22,790	23,613	24,252
20-24	114,811	22,104	22,537	22,907	23,337	23,926	112,543	21,573	22,029	22,472	22,906	23,563
25-29	153,143	29,534	29,935	30,339	31,423	31,912	168,475	32,875	33,622	33,870	34,166	33,942
30-34	175,546	34,728	34,819	34,769	35,250	35,980	192,579	37,233	37,923	38,540	39,186	39,697
35-39	182,095	34,728	35,736	36,428	37,314	37,889	188,839	35,882	36,716	37,812	38,784	39,645
40-44	157,343	29,361	29,991	31,119	32,570	34,302	168,557	31,399	32,447	33,518	34,728	36,465
45-49	142,246	26,751	27,989	28,603	29,218	29,685	151,513	28,494	29,676	30,328	31,173	31,842
50-54	124,519	23,029	24,180	25,299	25,773	26,238	135,339	25,129	26,479	27,527	27,905	28,299
55-59	101,870	18,566	19,313	20,134	21,380	22,477	111,578	20,166	21,073	22,092	23,436	24,811
60-64	80,763	14,135	15,200	16,428	17,196	17,804	90,051	15,831	16,876	18,323	19,281	19,740
65-69	58,616	10,549	11,007	11,552	12,317	13,191	63,668	10,955	11,842	12,613	13,511	14,747
70-74	41,042	6,989	7,540	8,176	8,816	9,521	43,685	7,556	8,107	8,669	9,270	10,083
75-79	23,488	3,864	4,178	4,585	5,156	5,705	28,355	4,855	5,168	5,593	6,120	6,619
80-84	11,688	1,952	2,119	2,297	2,507	2,813	17,253	2,982	3,196	3,407	3,677	3,991
85+	7,705	1,279	1,379	1,500	1,672	1,875	13,100	2,233	2,352	2,562	2,828	3,125
Total	1,912,249	359,905	371,209	381,880	393,986	405,269	2,007,815	376,518	389,676	402,004	414,001	425,616

Hispanic^a

	Male						Female					
	2008-12	2008	2009	2010	2011	2012	2008-12	2008	2009	2010	2011	2012
<1	75,250	14,325	14,417	14,675	15,629	16,204	72,151	13,909	13,915	13,959	14,932	15,436
01-04	282,959	54,174	55,240	56,620	57,757	59,168	272,102	52,076	53,259	54,442	55,514	56,811
05-09	324,142	59,291	63,001	65,255	67,194	69,401	309,794	56,002	60,023	62,464	64,513	66,792
10-14	308,092	58,650	59,900	62,060	63,256	64,226	292,460	55,575	57,059	58,921	59,850	61,055
15-19	326,140	62,987	65,120	66,116	66,176	65,741	299,904	57,653	59,347	60,547	61,245	61,112
20-24	347,424	65,791	67,848	70,226	71,196	72,363	298,408	56,030	57,911	60,380	61,326	62,761
25-29	358,755	71,096	71,424	71,813	72,203	72,219	317,489	62,279	63,599	64,228	64,022	63,361
30-34	349,122	66,104	67,831	69,873	71,831	73,483	323,984	60,971	63,090	65,221	66,686	68,016
35-39	320,449	61,012	63,061	64,229	65,306	66,841	306,543	59,070	60,682	61,549	62,098	63,144
40-44	296,940	56,748	57,670	59,423	60,871	62,228	295,239	57,084	57,729	58,937	60,238	61,251
45-49	266,439	49,177	51,667	53,525	55,411	56,659	272,012	50,588	52,666	54,640	56,359	57,759
50-54	211,181	37,560	39,750	42,327	44,527	47,017	223,558	40,140	42,626	45,077	46,881	48,834
55-59	153,878	27,134	28,803	30,585	32,626	34,730	172,599	30,673	32,527	34,227	36,445	38,727
60-64	111,795	19,743	21,051	22,449	23,728	24,824	130,244	23,256	24,572	26,330	27,613	28,473
65-69	75,904	13,611	14,053	14,915	16,026	17,299	95,197	17,054	17,960	18,831	19,943	21,409
70-74	52,679	9,465	10,121	10,587	11,035	11,471	70,630	12,840	13,422	14,138	14,793	15,437
75-79	34,770	6,227	6,494	6,931	7,319	7,799	51,001	9,211	9,692	10,256	10,685	11,157
80-84	21,255	3,724	4,014	4,280	4,518	4,719	34,821	6,110	6,617	6,936	7,349	7,809
85+	14,556	2,375	2,594	2,849	3,190	3,548	28,213	4,810	5,115	5,544	6,099	6,645
Total	3,931,730	739,194	764,059	788,738	809,799	829,940	3,866,349	725,331	751,811	776,627	796,591	815,989

*Hispanic includes all races.
Source: The National Cancer Institute's SEER Program (URL: http://www.seer.cancer.gov/popdata/index.html).

Table 27. Age Distribution (%) of Incidence Cases in New Jersey, 2008-2012 All Races, Both Sexes

THI Ruces, Both Sexes										
Cancer Site	0-19	20-34	35-44	45-54	55-64	65-74	75-84	85+	All Ages	Total Cases
All Sites	0.9%	2.3%	5.0%	13.9%	23.2%	25.3%	20.7%	8.7%	100%	244,532
Male	1.0%	1.9%	3.3%	11.7%	25.2%	28.4%	21.3%	7.3%	100%	122,793
Female	0.9%	2.8%	6.7%	16.0%	21.1%	22.2%	20.2%	10.2%	100%	121,739
Oral Cavity and Pharynx	0.4%	2.0%	5.5%	19.5%	29.3%	22.0%	15.3%	6.1%	100%	5,121
Esophagus	0.0%	0.3%	1.9%	11.5%	24.4%	29.4%	22.1%	10.4%	100%	2,332
Stomach	0.0%	1.5%	4.0%	10.5%	18.9%	25.2%	25.1%	14.8%	100%	3,978
Colon and Rectum	0.1%	1.2%	3.8%	12.8%	19.2%	22.6%	25.5%	14.8%	100%	22,040
Male	0.0%	1.3%	4.0%	13.9%	21.6%	24.8%	24.1%	10.4%	100%	10,891
Female	0.1%	1.1%	3.7%	11.8%	16.9%	20.3%	26.9%	19.1%	100%	11,149
Colon excluding Rectum	0.1%	1.0%	3.3%	10.8%	17.5%	22.8%	27.5%	17.0%	100%	15,650
Rectum and Rectosigmoid	0.404	4.50/	- 40 <i>i</i>	45.50	22.22	22.00/	20.504	0.504	1000	5 200
Junction	0.1%	1.6%	5.1%	17.7%	23.3%	22.0%	20.6%	9.6%	100%	6,390
Liver and Intrahepatic Bile Duct	0.8%	1.0%	2.1%	13.4%	34.7%	22.5%	18.6%	7.0%	100%	3,557
Pancreas	0.0%	0.3%	1.6%	8.7%	20.9%	26.1%	28.0%	14.4%	100%	6,712
Larynx	0.0%	0.3%	2.4%	14.4%	28.7%	28.9%	19.3%	5.9%	100%	1,662
Lung and Bronchus	0.0%	0.2%	1.2%	7.9%	20.2%	31.3%	29.1%	10.0%	100%	29,501
Male	0.0%	0.2%	1.1%	7.7%	21.0%	32.1%	28.9%	9.0%	100%	14,600
Female Rongs and Joints	0.0%	0.3%	1.3%	8.1%	19.4%	30.6%	29.4%	11.0%	100%	14,901
Bones and Joints	24.9%	17.1%	9.7%	13.3%	11.8%	9.1%	9.5%	4.6%	100%	474
Soft Tissue including Heart Melanoma of the Skin	8.4%	8.1%	7.5%	15.5%	18.8%	17.2%	15.6%	8.9%	100%	1,695
	0.4%	4.5%	7.7%	16.9%	21.4%	21.4%	19.4%	8.2%	100%	10,448
Breast (female)	0.0%	1.7%	9.4%	22.7%	24.0%	21.0%	15.1%	6.2%	100%	34,776
Cervix Uteri	0.2%	9.6%	22.0%	25.5%	18.5%	14.0%	6.8%	3.5%	100%	1,957
Corpus and Uterus, NOS	0.0%	1.0%	3.8%	16.6%	32.9%	27.2%	14.0%	4.6%	100%	8,338
Ovary	1.0%	3.2%	6.5%	19.1%	24.0%	21.2%	16.9%	8.1%	100%	3,513
Prostate	0.0%	0.0%	0.7%	10.7%	33.0%	35.8%	16.7%	3.2%	100%	35,641
Testis	5.5%	44.8%	24.9%	14.4%	7.0%	1.7%	1.4%	0.3%	100%	1,210
Urinary Bladder	0.0%	0.4%	1.2%	6.4%	17.7%	27.9%	31.8%	14.7%	100%	11,839
Kidney and Renal Pelvis	1.2%	1.7%	5.7%	16.4%	25.2%	26.1%	17.6%	6.1%	100%	7,644
Brain and Other Nervous System	12.7%	8.3%	8.1%	13.6%	19.7%	17.4%	15.0%	5.2%	100%	3,286
Thyroid Hodgkin Lymphoma	1.6%	12.8%	20.1%	25.8%	20.7%	11.8%	5.8%	1.4%	100%	8,593
Non-Hodgkin Lymphoma	13.1%	28.1%	14.6%	13.5%	10.8%	10.3%	6.9%	2.8%	100%	1,478
Myeloma	1.7% 0.1%	3.6% 0.7%	5.8% 3.1%	12.9% 12.3%	20.1%	23.0%	23.2%	9.7% 9.2%	100% 100%	10,302 3,339
Leukemia										
Lymphocytic Leukemia	7.5%	4.0%	4.7%	11.2%	17.3%	21.4%	22.4%	11.5%	100%	6,875
Acute Lymphocytic Leukemia	10.6% 53.1%	2.1% 9.2%	3.0% 5.3%	9.0%	18.0% 6.6%	22.6% 9.2%	5.5%	2.0%	100%	3,532 693
Chronic Lymphocytic Leukemia										
Acute Myeloid Leukemia	0.0% 4.8%	0.3% 5.3%	1.9% 5.7%	10.5%	20.3% 16.9%	26.8%	26.7% 24.9%	13.5%	100%	2,587 1,934
Acute Myelold Leukemia Acute Monocytic Leukemia	8.0%	3.2%	4.8%	8.0%	21.6%	24.0%	20.0%	10.4%	100%	1,934
Chronic Myeloid Leukemia	2.2%	8.2%	9.5%	16.2%	17.2%	20.2%	18.4%	8.1%	100%	814
Other Leukemia	5.2%	4.6%	4.6%	10.2%	11.8%	17.8%	22.4%	23.5%	100%	366
Mesothelioma	0.0%	0.7%	1.5%	6.7%	12.7%	27.5%	32.8%	18.2%	100%	677
Kaposi Sarcoma										
Kaposi Saiconia	0.5%	19.6%	15.9%	14.8%	11.1%	10.1%	14.3%	13.8%	100%	189

^{*} Include all invasive cancers in ICD-O-3.

Table 28. Median Age of Cancer Patients at Diagnosis, New Jersey 2008-2012 By Primary Cancer Site, Race and Sex

		All			White		Black		
Cancer Site	Total	Male	Female	Total	Male	Female	Total	Male	Female
All Sites	66	67	66	67	67	66	63	64	63
Oral Cavity and Pharynx	62	61	65	63	62	66	60	60	58
Esophagus	68	67	72	68	67	73	66	66	67
Stomach	71	69	73	72	70	74	68	67	70
Colon and Rectum	70	68	73	72	69	74	66	65	67
Colon excluding Rectum	72	70	75	74	71	76	67	66	68
Rectum and Rectosigmoid									
Junction	65	65	67	66	66	68	63	62	65
Liver and Intrahepatic Bile Duct	64	62	70	65	63	71	60	59	63
Pancreas	72	69	75	73	70	76	68	65	70
Larynx	66	66	64	66	67	65	63	63	63
Lung and Bronchus	71	71	71	72	71	72	68	67	68
Bones and Joints	44	42	46	44	43	47	24	20	28
Soft Tissue including Heart	60	60	60	62	62	62	51	49	52
Melanoma of the Skin	64	66	61	65	66	62	55	58	55
Breast	62	67	61	62	68	62	59	64	59
Cervix Uteri	51	*	51	51	*	51	54	*	54
Corpus and Uterus, NOS	63	*	63	63	*	63	65	*	65
Ovary	63	*	63	64	*	64	63	*	63
Prostate	66	66	*	66	66	*	64	64	*
Testis	34	34	*	34	34	*	38	38	*
Urinary Bladder	73	73	74	74	74	74	71	70	74
Kidney and Renal Pelvis	64	63	66	65	64	67	63	61	65
Brain and Other Nervous System	58	57	60	60	59	61	50	53	47
Thyroid	50	54	49	51	55	50	51	58	50
Hodgkin Lymphoma	41	43	37	42	44	39	39	42	35
Non-Hodgkin Lymphoma	67	66	69	68	67	70	58	56	62
Myeloma	68	68	69	69	69	70	65	66	65
Leukemia	67	66	69	68	67	70	61	59	65
Lymphocytic Leukemia	67	65	69	68	66	70	64	59	68
Acute Lymphocytic Leukemia	17	17	17	19	19	20	11	9	13
Chronic Lymphocytic Leukemia	71	69	73	72	70	74	70	69	74
Acute Myeloid Leukemia	68	68	68	69	69	70	61	59	62
Acute Monocytic Leukemia	67	67	69	68	68	71	26	30	16
Chronic Myeloid Leukemia	63	63	64	65	64	66	55	59	55
Other Leukemia	72	69	75	75	73	77	67	57	70
Mesothelioma	75	76	71	75	76	72	68	68	69
Kaposi Sarcoma	54	49	76	66	60	80	43	43	43

^{*} Non-applicable gender.